title,url,date,category
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity,https://lilly.mediaroom.com/2024-12-20-FDA-approves-Zepbound-R-tirzepatide-as-the-first-and-only-prescription-medicine-for-moderate-to-severe-obstructive-sleep-apnea-in-adults-with-obesity,2024-12-20T00:00:00,regulatory approval
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease,https://lilly.mediaroom.com/2024-12-17-Lillys-Kisunla-TM-donanemab-azbt-Approved-in-China-for-the-Treatment-of-Early-Symptomatic-Alzheimers-Disease,2024-12-17T00:00:00,regulatory approval
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt,https://lilly.mediaroom.com/2024-12-17-Lilly-and-EVA-Pharma-announce-regulatory-approval-and-release-of-locally-manufactured-insulin-in-Egypt,2024-12-17T00:00:00,regulatory approval
Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease,https://lilly.mediaroom.com/2024-12-13-Lillys-Omvoh-R-mirikizumab-recommended-by-CHMP-for-approval-in-the-European-Union-for-adults-with-moderately-to-severely-active-Crohns-disease,2024-12-13T00:00:00,regulatory approval
"Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer","https://lilly.mediaroom.com/2024-12-11-Lillys-Imlunestrant,-an-Oral-SERD,-Significantly-Improved-Progression-Free-Survival-as-Monotherapy-and-in-Combination-with-Verzenio-R-abemaciclib-in-Patients-with-ER-,-HER2-Advanced-Breast-Cancer",2024-12-11T00:00:00,clinical trial update
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting,https://lilly.mediaroom.com/2024-12-09-Phase-3-results-for-Lillys-Jaypirca-R-pirtobrutinib-in-covalent-BTK-inhibitor-pre-treated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-to-be-presented-at-the-2024-ASH-Annual-Meeting,2024-12-09T00:00:00,clinical trial update
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase,https://lilly.mediaroom.com/2024-12-09-Lilly-announces-new-15-billion-share-repurchase-program-and-seventh-consecutive-15-dividend-increase,2024-12-09T00:00:00,financial news
"CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade","https://lilly.mediaroom.com/2024-12-09-CORE-Kidney,-Boehringer-Ingelheim-and-Lilly-Are-Turning-Up-the-Volume-on-Kidney-Health-at-the-2025-Tournament-of-Roses-R-Parade",2024-12-09T00:00:00,commercialized drug update
Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin,https://lilly.mediaroom.com/2024-12-05-Lilly-announces-3-billion-expansion-of-its-recently-acquired-manufacturing-facility-in-Wisconsin,2024-12-05T00:00:00,commercialized drug update
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%,https://lilly.mediaroom.com/2024-12-04-Lillys-Zepbound-R-tirzepatide-superior-to-Wegovy-R-semaglutide-in-head-to-head-trial-showing-an-average-weight-loss-of-20-2-vs-13-7,2024-12-04T00:00:00,clinical trial update
Lilly announces changes on board of directors,https://lilly.mediaroom.com/2024-11-19-Lilly-announces-changes-on-board-of-directors,2024-11-19T00:00:00,management update
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose,https://lilly.mediaroom.com/2024-11-18-Lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-by-up-to-85-at-highest-tested-dose,2024-11-18T00:00:00,clinical trial update
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity,https://lilly.mediaroom.com/2024-11-16-Lillys-tirzepatide-reduced-the-risk-of-worsening-heart-failure-events-by-38-in-adults-with-heart-failure-with-preserved-ejection-fraction-HFpEF-and-obesity,2024-11-16T00:00:00,clinical trial update
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks,https://lilly.mediaroom.com/2024-11-13-Treatment-with-tirzepatide-in-adults-with-pre-diabetes-and-obesity-or-overweight-resulted-in-sustained-weight-loss-and-nearly-99-remained-diabetes-free-at-176-weeks,2024-11-13T00:00:00,clinical trial update
Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting,https://lilly.mediaroom.com/2024-11-05-Lilly-announces-details-of-presentations-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting,2024-11-05T00:00:00,clinical trial update
"Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium","https://lilly.mediaroom.com/2024-11-01-Lilly-to-Present-Results-from-Phase-3-EMBER-3-Study-of-Imlunestrant,-an-Oral-SERD,-and-Additional-Results-from-Its-Breast-Cancer-Portfolio-at-the-San-Antonio-Breast-Cancer-Symposium",2024-11-01T00:00:00,clinical trial update
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products,https://lilly.mediaroom.com/2024-10-30-Lilly-reports-Q3-2024-financial-results-highlighted-by-strong-volume-driven-revenue-growth-from-New-Products,2024-10-30T00:00:00,financial news
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study,https://lilly.mediaroom.com/2024-10-29-Modified-Titration-of-Donanemab-Demonstrated-Reduction-of-ARIA-E-in-Early-Symptomatic-Alzheimers-Disease-Patients-in-Phase-3b-study,2024-10-29T00:00:00,clinical trial update
Lilly declares fourth-quarter 2024 dividend,https://lilly.mediaroom.com/2024-10-28-Lilly-declares-fourth-quarter-2024-dividend,2024-10-28T00:00:00,financial news
"Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease","https://lilly.mediaroom.com/2024-10-28-Lillys-mirikizumab-is-first-and-only-IL23p19-antagonist-to-report-long-term,-multi-year,-sustained-efficacy-and-safety-data-for-both-ulcerative-colitis-and-Crohns-disease",2024-10-28T00:00:00,clinical trial update
Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab,https://lilly.mediaroom.com/2024-10-25-Lillys-EBGLYSS-TM-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-and-itch-relief-in-the-majority-of-patients-with-moderate-to-severe-atopic-dermatitis-who-discontinued-dupilumab,2024-10-25T00:00:00,clinical trial update
Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers,https://lilly.mediaroom.com/2024-10-23-Lillys-Kisunla-TM-donanemab-azbt-Receives-Marketing-Authorization-in-Great-Britain-for-the-Treatment-of-Mild-Cognitive-Impairment-and-Mild-Dementia-Due-to-Alzheimers-Disease-in-Adult-Patients-Who-Are-Apolipoprotein-E-4-Heterozygotes-or-Non-Carr,2024-10-23T00:00:00,regulatory approval
Lilly confirms date and conference call for third-quarter 2024 financial results announcement,https://lilly.mediaroom.com/2024-10-16-Lilly-confirms-date-and-conference-call-for-third-quarter-2024-financial-results-announcement,2024-10-16T00:00:00,financial news
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies,https://lilly.mediaroom.com/2024-10-16-Survey-reveals-8-in-10-Americans-with-ulcerative-colitis-struggle-to-find-a-public-restroom-during-emergencies,2024-10-16T00:00:00,commercialized drug update
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease,https://lilly.mediaroom.com/2024-10-14-Lilly-reports-one-year-histologic-outcomes-in-Phase-3-study-of-mirikizumab-compared-to-ustekinumab-for-Crohns-disease,2024-10-14T00:00:00,clinical trial update
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials,https://lilly.mediaroom.com/2024-10-02-Lilly-announces-new-4-5-billion-site-the-Lilly-Medicine-Foundry-to-drive-innovation-in-drug-production-and-make-medicines-for-clinical-trials,2024-10-02T00:00:00,commercialized drug update
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis,https://lilly.mediaroom.com/2024-09-25-New-data-show-Lillys-EBGLYSS-TM-lebrikizumab-lbkz-provided-sustained-disease-control-for-up-to-three-years-in-more-than-80-of-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis,2024-09-25T00:00:00,clinical trial update
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease,https://lilly.mediaroom.com/2024-09-24-Lillys-Kisunla-TM-donanemab-azbt-Approved-in-Japan-for-the-Treatment-of-Early-Symptomatic-Alzheimers-Disease,2024-09-24T00:00:00,regulatory approval
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis,https://lilly.mediaroom.com/2024-09-13-FDA-Approves-Lillys-EBGLYSS-TM-lebrikizumab-lbkz-for-Adults-and-Children-12-Years-and-Older-with-Moderate-to-Severe-Atopic-Dermatitis,2024-09-13T00:00:00,regulatory approval
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment,https://lilly.mediaroom.com/2024-09-12-Lilly-expands-manufacturing-footprint-in-Ireland-with-1-8-billion-investment,2024-09-12T00:00:00,commercialized drug update
"With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes","https://lilly.mediaroom.com/2024-09-10-With-once-a-week-dosing,-insulin-efsitora-alfa-delivers-similar-A1C-reduction-compared-to-daily-insulin-in-adults-with-type-1-diabetes",2024-09-10T00:00:00,clinical trial update
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes,https://lilly.mediaroom.com/2024-09-10-Once-weekly-dose-of-insulin-efsitora-alfa-delivers-A1C-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes,2024-09-10T00:00:00,clinical trial update
Lilly appoints Lucas Montarce as executive vice president and chief financial officer,https://lilly.mediaroom.com/2024-09-09-Lilly-appoints-Lucas-Montarce-as-executive-vice-president-and-chief-financial-officer,2024-09-09T00:00:00,management update
"In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin","https://lilly.mediaroom.com/2024-09-05-In-a-first-of-its-kind-fixed-dose-study,-once-weekly-insulin-efsitora-alfa-leads-to-A1C-reduction-similar-to-daily-insulin",2024-09-05T00:00:00,clinical trial update
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries,https://lilly.mediaroom.com/2024-09-04-Lilly-and-EVA-Pharma-collaborate-to-expand-access-to-baricitinib-in-low-to-middle-income-countries,2024-09-04T00:00:00,commercialized drug update
"Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity","https://lilly.mediaroom.com/2024-08-27-Lilly-releases-Zepbound-R-tirzepatide-single-dose-vials,-expanding-supply-and-access-for-adults-living-with-obesity",2024-08-27T00:00:00,commercialized drug update
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference,https://lilly.mediaroom.com/2024-08-22-Lilly-to-participate-in-Morgan-Stanley-22nd-Annual-Global-Healthcare-Conference,2024-08-22T00:00:00,financial news
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight,https://lilly.mediaroom.com/2024-08-20-Tirzepatide-reduced-the-risk-of-developing-type-2-diabetes-by-94-in-adults-with-pre-diabetes-and-obesity-or-overweight,2024-08-20T00:00:00,clinical trial update
Lilly announces retirement of Marschall S. Runge from its Board of Directors,https://lilly.mediaroom.com/2024-08-16-Lilly-announces-retirement-of-Marschall-S-Runge-from-its-Board-of-Directors,2024-08-16T00:00:00,management update
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease,https://lilly.mediaroom.com/2024-08-16-Lilly-Completes-Acquisition-of-Morphic-to-Improve-Outcomes-and-Expand-Options-for-People-Living-with-Inflammatory-Bowel-Disease,2024-08-16T00:00:00,commercialized drug update
Lilly opens state-of-the-art research and development center in the Boston Seaport,https://lilly.mediaroom.com/2024-08-13-Lilly-opens-state-of-the-art-research-and-development-center-in-the-Boston-Seaport,2024-08-13T00:00:00,commercialized drug update
"Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion","https://lilly.mediaroom.com/2024-08-08-Lilly-Reports-Q2-2024-Financial-Results,-Raises-Full-Year-Revenue-Guidance-by-3-Billion",2024-08-08T00:00:00,financial news
Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity,https://lilly.mediaroom.com/2024-08-01-Lillys-tirzepatide-successful-in-phase-3-study-showing-benefit-in-adults-with-heart-failure-with-preserved-ejection-fraction-and-obesity,2024-08-01T00:00:00,clinical trial update
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement,https://lilly.mediaroom.com/2024-07-25-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2024-Financial-Results-Announcement,2024-07-25T00:00:00,financial news
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease,https://lilly.mediaroom.com/2024-07-08-Lilly-to-Acquire-Morphic-to-Improve-Outcomes-for-Patients-with-Inflammatory-Bowel-Disease,2024-07-08T00:00:00,commercialized drug update
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease,https://lilly.mediaroom.com/2024-07-02-Lillys-Kisunla-TM-donanemab-azbt-Approved-by-the-FDA-for-the-Treatment-of-Early-Symptomatic-Alzheimers-Disease,2024-07-02T00:00:00,regulatory approval
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria,https://lilly.mediaroom.com/2024-06-25-Lilly-collaborates-with-OpenAI-to-discover-novel-medicines-to-treat-drug-resistant-bacteria,2024-06-25T00:00:00,commercialized drug update
Lilly Declares Third-Quarter 2024 Dividend,https://lilly.mediaroom.com/2024-06-24-Lilly-Declares-Third-Quarter-2024-Dividend,2024-06-24T00:00:00,financial news
"Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution","https://lilly.mediaroom.com/2024-06-21-Lillys-tirzepatide-reduced-obstructive-sleep-apnea-OSA-severity,-with-up-to-51-5-of-participants-meeting-the-criteria-for-disease-resolution",2024-06-21T00:00:00,clinical trial update
"Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks","https://lilly.mediaroom.com/2024-06-08-Lillys-tirzepatide-was-superior-to-placebo-for-MASH-resolution,-and-more-than-half-of-patients-achieved-improvement-in-fibrosis-at-52-weeks",2024-06-08T00:00:00,clinical trial update
"Lilly announces departure of Anat Ashkenazi, chief financial officer","https://lilly.mediaroom.com/2024-06-05-Lilly-announces-departure-of-Anat-Ashkenazi,-chief-financial-officer",2024-06-05,management update
Melissa Seymour to join Lilly as executive vice president of Global Quality,https://lilly.mediaroom.com/2024-06-04-Melissa-Seymour-to-join-Lilly-as-executive-vice-president-of-Global-Quality,2024-06-04,management update
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting,https://lilly.mediaroom.com/2024-06-01-Updated-Data-from-the-Phase-1-2-Study-of-Olomorasib-in-KRAS-G12C-Mutant-Advanced-Solid-Tumors-Presented-at-the-2024-ASCO-R-Annual-Meeting,2024-06-01,clinical trial update
"Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases","https://lilly.mediaroom.com/2024-05-29-Lilly,-UNICEF-expand-support-to-help-millions-of-young-people-at-risk-of-noncommunicable-diseases",2024-05-29,corporate social responsibility
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference,https://lilly.mediaroom.com/2024-05-28-Lilly-to-Participate-in-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference,2024-05-28,financial news
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines,https://lilly.mediaroom.com/2024-05-24-Lilly-Increases-Manufacturing-Investment-to-9-Billion-at-Newest-Indiana-Site-to-Boost-API-Production-for-Tirzepatide-and-Pipeline-Medicines,2024-05-24,management update
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,https://lilly.mediaroom.com/2024-05-23-Lilly-Announces-Details-of-Presentations-at-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting,2024-05-23,clinical trial update
"More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure","https://lilly.mediaroom.com/2024-05-21-More-than-one-half-of-patients-with-Crohns-disease-treated-with-Lillys-mirikizumab-achieved-clinical-remission-at-one-year,-including-patients-with-previous-biologic-failure",2024-05-21,clinical trial update
"With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin","https://lilly.mediaroom.com/2024-05-16-With-Once-a-Week-Dosing,-Insulin-Efsitora-Alfa-Delivers-A1C-Reduction-and-Safety-Profile-Consistent-with-Daily-Insulin",2024-05-16,clinical trial update
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer,https://lilly.mediaroom.com/2024-05-15-Alonzo-Weems-to-Retire-as-Executive-Vice-President-of-Enterprise-Risk-Management-and-Chief-Ethics-and-Compliance-Officer,2024-05-15,management update
Lilly Declares Second-Quarter 2024 Dividend,https://lilly.mediaroom.com/2024-05-06-Lilly-Declares-Second-Quarter-2024-Dividend,2024-05-06,financial news
"Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum","https://lilly.mediaroom.com/2024-04-30-Lilly-Reports-First-Quarter-2024-Financial-Results-and-Raises-Full-Year-Revenue-Guidance-by-2-Billion,-Highlights-Pipeline-Momentum",2024-04-30,financial news
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity,https://lilly.mediaroom.com/2024-04-17-Tirzepatide-reduced-sleep-apnea-severity-by-up-to-nearly-two-thirds-in-adults-with-obstructive-sleep-apnea-OSA-and-obesity,2024-04-17,clinical trial update
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement,https://lilly.mediaroom.com/2024-04-16-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2024-Financial-Results-Announcement,2024-04-16,financial news
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study,https://lilly.mediaroom.com/2024-03-10-More-than-two-thirds-of-people-with-atopic-dermatitis-and-skin-of-color-experienced-skin-improvement-in-a-first-of-its-kind-lebrikizumab-study,2024-03-10,clinical trial update
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab,https://lilly.mediaroom.com/2024-03-08-U-S-Food-and-Drug-Administration-to-Convene-Advisory-Committee-Meeting-to-Discuss-the-TRAILBLAZER-ALZ-2-Study-of-Donanemab,2024-03-08,regulatory approval
Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care,https://lilly.mediaroom.com/2024-03-07-Lillys-Newest-Phase-of-Get-Better-Campaign-Challenges-Misperceptions-About-Obesity-Care,2024-03-07,commercialized drug update
Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting,https://lilly.mediaroom.com/2024-03-05-Lilly-Announces-Details-of-Presentations-at-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting,2024-03-05,clinical trial update
Lilly to Participate in Cowen's 44th Annual Health Care Conference,https://lilly.mediaroom.com/2024-02-20-Lilly-to-Participate-in-Cowens-44th-Annual-Health-Care-Conference,2024-02-20,financial news
Philip Johnson to Retire as Lilly Treasurer,https://lilly.mediaroom.com/2024-02-09-Philip-Johnson-to-Retire-as-Lilly-Treasurer,2024-02-09,management update
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance,https://lilly.mediaroom.com/2024-02-06-Lilly-Reports-Strong-Fourth-Quarter-2023-Financial-Results-and-Provides-2024-Guidance,2024-02-06,financial news
Johna Norton to Retire as Lilly Executive Vice President of Global Quality,https://lilly.mediaroom.com/2024-01-25-Johna-Norton-to-Retire-as-Lilly-Executive-Vice-President-of-Global-Quality,2024-01-25,management update
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting,https://lilly.mediaroom.com/2024-01-23-Positive-Phase-1-2-Clinical-Trial-Data-for-an-Investigational-Gene-Therapy-for-Genetic-Hearing-Loss-to-be-Presented-at-the-Association-for-Research-in-Otolaryngology-2024-MidWinter-Meeting,2024-01-23,clinical trial update
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance,https://lilly.mediaroom.com/2024-01-23-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2023-Financial-Results-and-2024-Financial-Guidance,2024-01-23,financial news
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™,https://lilly.mediaroom.com/2024-01-04-Lilly-Launches-End-to-End-Digital-Healthcare-Experience-through-LillyDirect-TM,2024-01-04,commercialized drug update
Lilly to Participate in J.P. Morgan Healthcare Conference,https://lilly.mediaroom.com/2024-01-02-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference,2024-01-02,financial news
Lilly Completes Acquisition of POINT Biopharma,https://lilly.mediaroom.com/2023-12-27-Lilly-Completes-Acquisition-of-POINT-Biopharma,2023-12-27,management update
"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023","https://lilly.mediaroom.com/2023-12-18-Lilly-Extends-Tender-Offer-to-Acquire-POINT-Biopharma-to-Dec-22,-2023",2023-12-18,management update
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting,https://lilly.mediaroom.com/2023-12-11-Updated-Data-from-the-BRUIN-Phase-1-2-Study-of-Pirtobrutinib-in-Chronic-Lymphocytic-Leukemia-and-Mantle-Cell-Lymphoma-Presented-at-the-2023-ASH-Annual-Meeting,2023-12-11,clinical trial update
"Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks","https://lilly.mediaroom.com/2023-12-11-Lillys-Zepbound-TM-tirzepatide-achieved-additional-6-7-weight-loss-following-a-36-week-open-label-lead-in-period,-for-a-total-mean-weight-loss-of-26-0-from-study-entry-over-88-weeks",2023-12-11,clinical trial update
"Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend","https://lilly.mediaroom.com/2023-12-08-Lilly-Announces-15-Dividend-Increase,-First-Quarter-2024-Dividend",2023-12-08,financial news
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium,https://lilly.mediaroom.com/2023-12-05-Lilly-to-Present-Final-Overall-Survival-Analysis-from-the-MONARCH-3-Study-of-Verzenio-R-abemaciclib-and-Additional-Results-from-Its-Breast-Cancer-Portfolio-at-the-2023-San-Antonio-Breast-Cancer-Symposium,2023-12-05,clinical trial update
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity,https://lilly.mediaroom.com/2023-12-05-Zepbound-TM-tirzepatide-is-Now-Available-in-U-S-Pharmacies-for-Adults-Living-with-Obesity,2023-12-05,commercialized drug update
"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023","https://lilly.mediaroom.com/2023-12-04-Lilly-Extends-Tender-Offer-to-Acquire-POINT-Biopharma-to-Dec-15,-2023",2023-12-04,management update
"Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor","https://lilly.mediaroom.com/2023-12-01-Jaypirca-R-pirtobrutinib-Now-Approved-by-U-S-FDA-for-the-Treatment-of-Adult-Patients-with-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-Who-Have-Received-at-Least-Two-Lines-of-Therapy,-Including-a-BTK-Inhibitor-and-a-BCL-2-Inhibito",2023-12-01,regulatory approval
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego,https://lilly.mediaroom.com/2023-11-28-Lilly-Announces-Plans-to-Open-its-First-ever-Gateway-Labs-Site-in-San-Diego,2023-11-28,management update
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany,https://lilly.mediaroom.com/2023-11-17-Lilly-to-expand-injectable-manufacturing-capacity-with-planned-2-5-billion-site-in-Germany,2023-11-17,management update
"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023","https://lilly.mediaroom.com/2023-11-17-Lilly-Extends-Tender-Offer-to-Acquire-POINT-Biopharma-to-Dec-1,-2023",2023-11-17,management update
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma,https://lilly.mediaroom.com/2023-11-14-Lilly-Announces-the-Receipt-of-NRC-Consent-in-Connection-with-its-Proposed-Acquisition-of-POINT-Biopharma,2023-11-14,management update
Lilly to Participate in Evercore ISI HealthCONx Conference,https://lilly.mediaroom.com/2023-11-14-Lilly-to-Participate-in-Evercore-ISI-HealthCONx-Conference,2023-11-14,financial news
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma,https://lilly.mediaroom.com/2023-11-08-Lilly-Announces-Extension-of-Tender-Offer-to-Acquire-POINT-Biopharma,2023-11-08,management update
"FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems","https://lilly.mediaroom.com/2023-11-08-FDA-Approves-Lillys-Zepbound-TM-tirzepatide-for-Chronic-Weight-Management,-a-Powerful-New-Option-for-the-Treatment-of-Obesity-or-Overweight-with-Weight-Related-Medical-Problems",2023-11-08,regulatory approval
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting,https://lilly.mediaroom.com/2023-11-02-Lilly-Announces-Details-of-Pirtobrutinib-Presentations-in-B-Cell-Malignancies-at-2023-ASH-Annual-Meeting,2023-11-02,clinical trial update
"Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity","https://lilly.mediaroom.com/2023-11-02-Lilly-Reports-Third-Quarter-2023-Financial-Results,-Highlights-Strong-Sales-Growth-and-Business-Development-Activity",2023-11-02,financial news
"Hip-Hop Classic ""It Takes Two"" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease",https://lilly.mediaroom.com/2023-11-01-Hip-Hop-Classic-It-Takes-Two-Takes-on-New-Meaning-in-Remix-to-Elevate-Importance-of-Testing-for-Kidney-Disease,2023-11-01,commercialized drug update
Lilly Declares Fourth-Quarter 2023 Dividend,https://lilly.mediaroom.com/2023-11-01-Lilly-Declares-Fourth-Quarter-2023-Dividend,2023-11-01,financial news
"FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis","https://lilly.mediaroom.com/2023-10-26-FDA-Approves-Lillys-Omvoh-TM-mirikizumab-mrkz-,-A-First-in-Class-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis",2023-10-26,regulatory approval
Lilly to Participate in UBS Biopharma Conference 2023,https://lilly.mediaroom.com/2023-10-26-Lilly-to-Participate-in-UBS-Biopharma-Conference-2023,2023-10-26,financial news
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023,https://lilly.mediaroom.com/2023-10-21-Lillys-Retevmo-R-selpercatinib-Phase-3-Results-in-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-and-RET-Mutant-Medullary-Thyroid-Cancer-Both-Published-in-The-New-England-Journal-of-Medicine-and-Presented-in-a-Presidential-Symposium-at-ESMO-Con,2023-10-21,clinical trial update
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement,https://lilly.mediaroom.com/2023-10-20-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2023-Financial-Results-Announcement,2023-10-20,financial news
Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer,https://lilly.mediaroom.com/2023-10-20-Landmark-5-Year-monarchE-Outcome-Data-Demonstrate-Verzenio-R-abemaciclib-s-Long-Term-Impact-on-Cancer-Recurrence-in-High-Risk-Early-Breast-Cancer,2023-10-20,clinical trial update
Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years,https://lilly.mediaroom.com/2023-10-20-Nearly-80-of-patients-with-moderate-to-severe-atopic-dermatitis-maintained-clear-or-almost-clear-skin-with-Lillys-lebrikizumab-monthly-maintenance-dosing-at-two-years,2023-10-20,clinical trial update
"Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks","https://lilly.mediaroom.com/2023-10-15-Lillys-tirzepatide-shows-additional-21-1-weight-loss-after-12-weeks-of-intensive-lifestyle-intervention,-for-a-total-mean-weight-loss-of-26-6-from-study-entry-over-84-weeks",2023-10-15,clinical trial update
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial,https://lilly.mediaroom.com/2023-10-12-Lillys-Mirikizumab-Helped-Patients-with-Crohns-Disease-Achieve-Long-Term-Remission-in-Phase-3-Trial,2023-10-12,clinical trial update
Lilly Announces Details of Presentations at ESMO Congress 2023,https://lilly.mediaroom.com/2023-10-06-Lilly-Announces-Details-of-Presentations-at-ESMO-Congress-2023,2023-10-06,clinical trial update
Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,https://lilly.mediaroom.com/2023-10-04-Loxo-Lilly-Unveils-Three-New-Oncology-Programs-at-2023-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics,2023-10-04,clinical trial update
Lilly Announces Leadership Transitions,https://lilly.mediaroom.com/2023-10-04-Lilly-Announces-Leadership-Transitions,2023-10-04,management update
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies,https://lilly.mediaroom.com/2023-10-03-Lilly-to-Acquire-POINT-Biopharma-to-Expand-Oncology-Capabilities-into-Next-Generation-Radioligand-Therapies,2023-10-03,commercialized drug update
U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer,https://lilly.mediaroom.com/2023-10-02-U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Lebrikizumab-Based-on-Inspection-Findings-at-Third-Party-Manufacturer,2023-10-02,regulatory approval
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease,https://lilly.mediaroom.com/2023-09-22-US-FDA-approves-Jardiance-R-for-the-treatment-of-adults-with-chronic-kidney-disease,2023-09-22,regulatory approval
Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference,https://lilly.mediaroom.com/2023-08-29-Lilly-to-Participate-in-Morgan-Stanley-21st-Annual-Global-Healthcare-Conference,2023-08-29,financial news
Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer,https://lilly.mediaroom.com/2023-08-22-Lillys-Retevmo-R-selpercatinib-Demonstrates-Superior-Progression-Free-Survival-Compared-to-Approved-Multikinase-Inhibitors-in-RET-Mutant-Medullary-Thyroid-Cancer,2023-08-22,clinical trial update
Lilly Completes Acquisition of Versanis Bio,https://lilly.mediaroom.com/2023-08-14-Lilly-Completes-Acquisition-of-Versanis-Bio,2023-08-14,commercialized drug update
Lilly Completes Acquisition of Sigilon Therapeutics,https://lilly.mediaroom.com/2023-08-14-Lilly-Completes-Acquisition-of-Sigilon-Therapeutics,2023-08-14,commercialized drug update
Lilly Completes Acquisition of DICE Therapeutics,https://lilly.mediaroom.com/2023-08-09-Lilly-Completes-Acquisition-of-DICE-Therapeutics,2023-08-09,commercialized drug update
"Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements","https://lilly.mediaroom.com/2023-08-08-Lilly-Reports-Second-Quarter-2023-Financial-Results,-Highlights-Accelerating-Revenue-Growth-and-Key-Pipeline-Advancements",2023-08-08,financial news
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/2023-08-04-Lillys-Retevmo-R-selpercatinib-is-the-First-Targeted-Therapy-to-Demonstrate-Superior-Progression-Free-Survival-Compared-to-a-PD-1-Inhibitor-Plus-Chemotherapy-for-Adults-with-Newly-Diagnosed-Advanced-or-Metastatic-RET-Fusion-Positive-Non-Small-C,2023-08-04,clinical trial update
Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies,https://lilly.mediaroom.com/2023-07-27-Tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies,2023-07-27,clinical trial update
Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement,https://lilly.mediaroom.com/2023-07-25-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2023-Financial-Results-Announcement,2023-07-25,financial news
Lilly Announces Extension of Tender Offer to Acquire DICE,https://lilly.mediaroom.com/2023-07-25-Lilly-Announces-Extension-of-Tender-Offer-to-Acquire-DICE,2023-07-25,commercialized drug update
Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA,https://lilly.mediaroom.com/2023-07-17-Results-from-Lillys-Landmark-Phase-3-Trial-of-Donanemab-Presented-at-Alzheimers-Association-Conference-and-Published-in-JAMA,2023-07-17,clinical trial update
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases,https://lilly.mediaroom.com/2023-07-14-Lilly-to-Acquire-Versanis-to-Improve-Patient-Outcomes-in-Cardiometabolic-Diseases,2023-07-14,commercialized drug update
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC,https://lilly.mediaroom.com/2023-07-11-Lilly-Announces-Webcast-to-Provide-Alzheimers-Disease-Update-at-AAIC,2023-07-11,clinical trial update
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,https://lilly.mediaroom.com/2023-07-06-New-England-Journal-of-Medicine-Publishes-BRUIN-Phase-1-2-Trial-Data-for-Pirtobrutinib-in-BTK-Inhibitor-Pre-Treated-Adult-Patients-with-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma,2023-07-06,clinical trial update
Lilly to Acquire Sigilon Therapeutics,https://lilly.mediaroom.com/2023-06-29-Lilly-to-Acquire-Sigilon-Therapeutics,2023-06-29,commercialized drug update
Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight,https://lilly.mediaroom.com/2023-06-26-Lillys-phase-2-retatrutide-results-published-in-The-New-England-Journal-of-Medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-and-overweight,2023-06-26,clinical trial update
Lilly Declares Third-Quarter 2023 Dividend,https://lilly.mediaroom.com/2023-06-26-Lilly-Declares-Third-Quarter-2023-Dividend,2023-06-26,financial news
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes,https://lilly.mediaroom.com/2023-06-24-Lillys-SURMOUNT-2-results-published-in-The-Lancet-show-tirzepatide-achieved-a-mean-weight-reduction-of-15-7-at-the-highest-dose-15-mg-in-adults-with-obesity-or-overweight-and-type-2-diabetes,2023-06-24,clinical trial update
"Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight","https://lilly.mediaroom.com/2023-06-23-Lillys-phase-2-results-published-in-the-New-England-Journal-of-Medicine-show-orforglipron,-a-once-daily-oral-nonpeptide-GLP-1-receptor-agonist,-achieved-up-to-14-7-mean-weight-reduction-at-36-weeks-in-adults-with-obesity-or-overweight",2023-06-23,clinical trial update
US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older,https://lilly.mediaroom.com/2023-06-21-US-FDA-approves-Jardiance-R-empagliflozin-for-the-treatment-of-type-2-diabetes-in-children-10-years-and-older,2023-06-21,regulatory approval
Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions,https://lilly.mediaroom.com/2023-06-20-Lilly-to-present-new-research-in-the-treatment-of-diabetes-and-obesity-at-the-American-Diabetes-Associations-R-83rd-Scientific-Sessions,2023-06-20,clinical trial update
"Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch ""Tap the Cap""",https://lilly.mediaroom.com/2023-06-20-Lilly-Teams-up-with-the-American-Diabetes-Association-and-Adam-Duvall-to-Launch-Tap-the-Cap,2023-06-20,commercialized drug update
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology,https://lilly.mediaroom.com/2023-06-20-Lilly-to-Acquire-DICE-Therapeutics-to-Advance-Innovation-in-Immunology,2023-06-20,commercialized drug update
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention,https://lilly.mediaroom.com/2023-06-16-First-Of-Its-Kind-Head-to-Head-Clinical-Trial-Reaffirms-the-Efficacy-of-Emgality-in-Episodic-Migraine-Prevention,2023-06-16,clinical trial update
Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting,https://lilly.mediaroom.com/2023-06-02-Lilly-Highlights-Verzenio-R-abemaciclib-and-Jaypirca-TM-pirtobrutinib-Data-at-2023-ASCO-R-Annual-Meeting,2023-06-02,clinical trial update
Lilly to Participate in Goldman Sachs Global Healthcare Conference,https://lilly.mediaroom.com/2023-05-30-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference,2023-05-30,financial news
Lilly ESG Report Highlights Progress Towards Sustainability Goals,https://lilly.mediaroom.com/2023-05-22-Lilly-ESG-Report-Highlights-Progress-Towards-Sustainability-Goals,2023-05-22,corporate responsibility
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine,https://lilly.mediaroom.com/2023-05-18-Lillys-peresolimab-Phase-2a-rheumatoid-arthritis-trial-published-in-The-New-England-Journal-of-Medicine,2023-05-18,clinical trial update
Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting,https://lilly.mediaroom.com/2023-05-11-Loxo-Lilly-Announces-Details-of-Presentations-at-2023-European-Hematology-Association-EHA-Annual-Meeting,2023-05-11,clinical trial update
Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation,https://lilly.mediaroom.com/2023-05-09-Lillys-Social-Impact-Venture-Capital-Portfolio-Poised-to-Grow-to-300-Million-with-New-50-Million-Allocation,2023-05-09,corporate responsibility
"Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis","https://lilly.mediaroom.com/2023-05-09-Lilly-Discloses-First-in-Class,-Interim-Phase-2-Data-in-Pediatric-Patients-and-New-Analysis-from-Phase-3-Program-in-Adult-Patients-for-Mirikizumab-in-Ulcerative-Colitis",2023-05-09,clinical trial update
Lilly to Participate in Bank of America Securities 2023 Healthcare Conference,https://lilly.mediaroom.com/2023-05-03-Lilly-to-Participate-in-Bank-of-America-Securities-2023-Healthcare-Conference,2023-05-03,financial news
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease,https://lilly.mediaroom.com/2023-05-03-Lillys-Donanemab-Significantly-Slowed-Cognitive-and-Functional-Decline-in-Phase-3-Study-of-Early-Alzheimers-Disease,2023-05-03,clinical trial update
"Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana","https://lilly.mediaroom.com/2023-05-02-Lilly-Provides-500,000-in-Grants-to-Support-Equitable-Access-to-Education-for-Dreamers-in-Indiana",2023-05-02,corporate responsibility
Lilly Declares Second-Quarter 2023 Dividend,https://lilly.mediaroom.com/2023-05-01-Lilly-Declares-Second-Quarter-2023-Dividend,2023-05-01,financial news
Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis,https://lilly.mediaroom.com/2023-05-01-Up-to-73-of-Atopic-Dermatitis-Patients-Taking-Lillys-Lebrikizumab-Had-Improved-or-Cleared-Skin-on-Face-or-Hands-in-New-Analysis,2023-05-01,clinical trial update
"Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum","https://lilly.mediaroom.com/2023-04-27-Lilly-Reports-First-Quarter-2023-Financial-Results,-Highlights-Continued-Core-Business-Growth-and-Pipeline-Momentum",2023-04-27,financial news
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2,https://lilly.mediaroom.com/2023-04-27-Lillys-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-SURMOUNT-2,2023-04-27,clinical trial update
Lilly to Divest BAQSIMI to Amphastar,https://lilly.mediaroom.com/2023-04-24-Lilly-to-Divest-BAQSIMI-to-Amphastar,2023-04-24,commercialized drug update
Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities,https://lilly.mediaroom.com/2023-04-17-Lilly-to-Make-Record-Breaking-Investment-in-Indiana-Manufacturing-Facilities,2023-04-17,corporate responsibility
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab,https://lilly.mediaroom.com/2023-04-13-U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Mirikizumab,"April 13, 2023",regulatory approval
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement,https://lilly.mediaroom.com/2023-04-13-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2023-Financial-Results-Announcement,"April 13, 2023",financial news
Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting,https://lilly.mediaroom.com/2023-03-14-Lilly-Announces-Details-of-Presentations-at-2023-American-Association-for-Cancer-Research-AACR-Annual-Meeting,"March 14, 2023",clinical trial update
Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease,https://lilly.mediaroom.com/2023-03-08-Lilly-Provides-Update-on-A4-Study-of-Solanezumab-for-Preclinical-Alzheimers-Disease,"March 08, 2023",clinical trial update
US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes,https://lilly.mediaroom.com/2023-03-08-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-for-children-10-years-and-older-with-type-2-diabetes,"March 08, 2023",regulatory approval
"Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study","https://lilly.mediaroom.com/2023-03-06-Intensive-education-at-clinics-about-multidisciplinary-care-improved-likelihood-that-adults-with-type-2-diabetes-and-cardiovascular-disease-were-receiving-guideline-directed-medicines,-according-to-real-world-study","March 06, 2023",clinical trial update
"U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer","https://lilly.mediaroom.com/2023-03-03-U-S-FDA-Broadens-Indication-for-Verzenio-R-abemaciclib-in-HR-,-HER2-,-Node-Positive,-High-Risk-Early-Breast-Cancer","March 03, 2023",regulatory approval
Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month,https://lilly.mediaroom.com/2023-03-01-Lilly-Cuts-Insulin-Prices-by-70-and-Caps-Patient-Insulin-Out-of-Pocket-Costs-at-35-Per-Month,"March 01, 2023",commercialized drug update
Lilly to Participate in Cowen's 43rd Annual Health Care Conference,https://lilly.mediaroom.com/2023-02-21-Lilly-to-Participate-in-Cowens-43rd-Annual-Health-Care-Conference,"February 21, 2023",management update
Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh,https://lilly.mediaroom.com/2023-02-13-Lilly-and-IABL-Collaborate-to-Ensure-Patient-Access-to-High-Quality-Affordable-Insulin-in-Bangladesh,"February 13, 2023",commercialized drug update
Lilly to Participate in SVB Securities Global Biopharma Conference,https://lilly.mediaroom.com/2023-02-07-Lilly-to-Participate-in-SVB-Securities-Global-Biopharma-Conference,"February 07, 2023",management update
Lilly to Participate in Guggenheim Oncology Conference,https://lilly.mediaroom.com/2023-02-03-Lilly-to-Participate-in-Guggenheim-Oncology-Conference,"February 03, 2023",management update
"Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook","https://lilly.mediaroom.com/2023-02-02-Lilly-Reports-Fourth-Quarter-2022-Financial-Results,-Core-Business-Growth-and-Pipeline-Advancements-Support-Strong-Long-Term-Outlook","February 02, 2023",financial news
"U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor","https://lilly.mediaroom.com/2023-01-27-U-S-FDA-Approves-Jaypirca-TM-pirtobrutinib-,-the-First-and-Only-Non-Covalent-Reversible-BTK-Inhibitor,-for-Adult-Patients-with-Relapsed-or-Refractory-Mantle-Cell-Lymphoma-After-at-Least-Two-Lines-of-Systemic-Therapy,-Including-a-BTK-Inhibitor","January 27, 2023",regulatory approval
Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity,https://lilly.mediaroom.com/2023-01-26-Lilly-Supports-Direct-Reliefs-Efforts-to-Expand-Access-to-Medicines-by-Improving-Cold-Chain-Capacity,"January 26, 2023",commercialized drug update
Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park,https://lilly.mediaroom.com/2023-01-24-Lilly-Plans-to-Invest-Additional-450-million-at-Manufacturing-Site-in-Research-Triangle-Park,"January 24, 2023",management update
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease,https://lilly.mediaroom.com/2023-01-20-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-for-adults-with-chronic-kidney-disease,"January 20, 2023",regulatory approval
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab,https://lilly.mediaroom.com/2023-01-19-U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Accelerated-Approval-of-Donanemab,"January 19, 2023",regulatory approval
Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement,https://lilly.mediaroom.com/2023-01-19-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2022-Financial-Results-Announcement,"January 19, 2023",financial news
Lilly to Participate in the J.P. Morgan Healthcare Conference,https://lilly.mediaroom.com/2023-01-04-Lilly-to-Participate-in-the-J-P-Morgan-Healthcare-Conference,"January 04, 2023",management update
Lilly and ProQR to Expand RNA Editing Collaboration,https://lilly.mediaroom.com/2022-12-22-Lilly-and-ProQR-to-Expand-RNA-Editing-Collaboration,"December 22, 2022",management update
Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa,https://lilly.mediaroom.com/2022-12-14-Lilly-and-EVA-Pharma-Announce-Collaboration-to-Enhance-Sustainable-Access-to-Affordable-Insulin-in-Africa,"December 14, 2022",commercialized drug update
"Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines","https://lilly.mediaroom.com/2022-12-13-Lilly-Announces-2023-Financial-Guidance,-Plans-to-Launch-up-to-Four-New-Medicines","December 13, 2022",financial news
Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting,https://lilly.mediaroom.com/2022-12-12-Loxo-Lilly-Presents-Updated-Pirtobrutinib-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-at-the-2022-American-Society-of-Hematology-Annual-Meeting,"December 12, 2022",clinical trial update
"Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend","https://lilly.mediaroom.com/2022-12-12-Lilly-Announces-15-Dividend-Increase,-First-Quarter-2023-Dividend","December 12, 2022",financial news
Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes,https://lilly.mediaroom.com/2022-12-07-Phase-III-trial-demonstrated-Jardiance-R-is-the-first-SGLT2-inhibitor-to-show-statistically-significant-reduction-in-blood-sugar-levels-in-children-and-adolescents-with-type-2-diabetes,"December 07, 2022",clinical trial update
Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology,https://lilly.mediaroom.com/2022-12-06-Lilly-Announces-Updated-Data-from-the-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Presented-at-SABCS-and-Simultaneously-Published-in-The-Lancet-Oncology,"December 06, 2022",clinical trial update
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases,https://lilly.mediaroom.com/2022-12-01-Lilly-Completes-Acquisition-of-Akouos-Expanding-Efforts-to-Help-People-with-Genetic-Diseases,"December 01, 2022",management update
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease,https://lilly.mediaroom.com/2022-11-30-Lilly-Shares-Positive-Donanemab-Data-in-First-Active-Comparator-Study-in-Early-Symptomatic-Alzheimers-Disease,"November 30, 2022",clinical trial update
Lilly and Akouos Announce Expiration of Akouos Tender Offer,https://lilly.mediaroom.com/2022-11-30-Lilly-and-Akouos-Announce-Expiration-of-Akouos-Tender-Offer,"November 30, 2022",management update
Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement,https://lilly.mediaroom.com/2022-11-29-Lilly-Confirms-Date-and-Conference-Call-for-2023-Financial-Guidance-Announcement,"November 29, 2022",financial news
Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium,https://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium,"November 21, 2022",clinical trial update
Lilly to Participate in Evercore ISI HealthCONx Conference,https://lilly.mediaroom.com/2022-11-16-Lilly-to-Participate-in-Evercore-ISI-HealthCONx-Conference,"November 16, 2022",management update
Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform,https://lilly.mediaroom.com/2022-11-07-Lilly-to-begin-rollout-of-Tempo-R-Personalized-Diabetes-Management-Platform,"November 07, 2022",commercialized drug update
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease,https://lilly.mediaroom.com/2022-11-04-Landmark-EMPA-KIDNEY-trial-showed-significant-benefit-of-Jardiance-R-in-reducing-kidney-disease-progression-or-cardiovascular-death-by-28-vs-placebo-in-people-with-chronic-kidney-disease,"November 04, 2022",clinical trial update
Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting,https://lilly.mediaroom.com/2022-11-03-Loxo-Lilly-Announces-Details-of-Presentations-at-the-2022-American-Society-of-Hematology-Annual-Meeting,"November 03, 2022",clinical trial update
Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress,https://lilly.mediaroom.com/2022-11-01-Lilly-Reports-Solid-Third-Quarter-2022-Financial-Results-and-Continued-Pipeline-Progress,"November 01, 2022",financial news
Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration,https://lilly.mediaroom.com/2022-10-27-Lilly-commits-92-5-million-to-Purdue-to-establish-an-innovative-pharmaceutical-manufacturing-scholarship-program-and-to-extend-research-collaboration,"October 27, 2022",management update
Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement,https://lilly.mediaroom.com/2022-10-19-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2022-Financial-Results-Announcement,"October 19, 2022",financial news
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss,https://lilly.mediaroom.com/2022-10-18-Lilly-to-Acquire-Akouos-to-Discover-and-Develop-Treatments-for-Hearing-Loss,"October 18, 2022",management update
Lilly Declares Fourth-Quarter 2022 Dividend,https://lilly.mediaroom.com/2022-10-17-Lilly-Declares-Fourth-Quarter-2022-Dividend,"October 17, 2022",financial news
"Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities","https://lilly.mediaroom.com/2022-10-06-Lilly-receives-U-S-FDA-Fast-Track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity,-or-overweight-with-weight-related-comorbidities","October 06, 2022",regulatory approval
"FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type","https://lilly.mediaroom.com/2022-09-21-FDA-Approves-Lillys-Retevmo-R-selpercatinib-,-the-First-and-Only-RET-Inhibitor-for-Adults-with-Advanced-or-Metastatic-Solid-Tumors-with-a-RET-Gene-Fusion,-Regardless-of-Type","September 21, 2022",regulatory approval
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials,https://lilly.mediaroom.com/2022-09-08-Lebrikizumab-Dosed-Every-Four-Weeks-Maintained-Durable-Skin-Clearance-in-Lillys-Phase-3-Monotherapy-Atopic-Dermatitis-Trials,"September 08, 2022",clinical trial update
Lilly Announces Details of Presentations at ESMO Congress 2022,https://lilly.mediaroom.com/2022-09-07-Lilly-Announces-Details-of-Presentations-at-ESMO-Congress-2022,"September 07, 2022",clinical trial update
Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference,https://lilly.mediaroom.com/2022-08-31-Lilly-to-Participate-in-Morgan-Stanley-20th-Annual-Global-Healthcare-Conference,"August 31, 2022",management update
Lilly to Participate in Citi's 17th Annual BioPharma Conference,https://lilly.mediaroom.com/2022-08-25-Lilly-to-Participate-in-Citis-17th-Annual-BioPharma-Conference,"August 25, 2022",management update
Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly,https://lilly.mediaroom.com/2022-08-11-Lilly-Announces-Leadership-Transition-in-Human-Resources-and-New-Chief-Commercial-Officer-for-Loxo-Lilly,"August 11, 2022",management update
"Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience","https://lilly.mediaroom.com/2022-08-08-Lillys-Taltz-R-ixekizumab-Now-Available-in-New,-Citrate-Free-Formulation-to-Reduce-Injection-Site-Pain-for-Improved-Patient-Experience","August 08, 2022",commercialized drug update
Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results,https://lilly.mediaroom.com/2022-08-04-Lilly-Updates-Conference-Call-Start-Time-for-Second-Quarter-2022-Financial-Results,"August 04, 2022",financial news
"Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements","https://lilly.mediaroom.com/2022-08-04-Lilly-Reports-Second-Quarter-Financial-Results,-Highlights-Momentum-of-New-Medicines-and-Pipeline-Advancements",2022-08-04,Financial news
Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement,https://lilly.mediaroom.com/2022-07-21-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2022-Financial-Results-Announcement,2022-07-21,Financial news
"Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options","https://lilly.mediaroom.com/2022-06-29-Lilly-will-supply-an-additional-150,000-doses-of-bebtelovimab-to-U-S-government-in-ongoing-effort-to-provide-COVID-19-treatment-options",2022-06-29,Commercialized drug update
Lilly Declares Third-Quarter 2022 Dividend,https://lilly.mediaroom.com/2022-06-27-Lilly-Declares-Third-Quarter-2022-Dividend,2022-06-27,Financial news
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata,https://lilly.mediaroom.com/2022-06-13-FDA-Approves-Lilly-and-Incytes-OLUMIANT-R-baricitinib-As-First-and-Only-Systemic-Medicine-for-Adults-with-Severe-Alopecia-Areata,2022-06-13,Regulatory approval
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials,https://lilly.mediaroom.com/2022-06-07-Eight-out-of-Ten-Patients-Maintained-Skin-Clearance-at-One-Year-in-Lillys-Lebrikizumab-Atopic-Dermatitis-Monotherapy-Trials,2022-06-07,Clinical trial update
New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®,https://lilly.mediaroom.com/2022-06-06-New-analyses-of-Mounjaro-TM-tirzepatide-injection-for-the-treatment-of-adults-with-type-2-diabetes-presented-at-the-American-Diabetes-Associations-R-82nd-Scientific-Sessions-R,2022-06-06,Clinical trial update
Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study,https://lilly.mediaroom.com/2022-06-05-Jardiance-R-decreased-relative-risk-of-hospitalization-for-heart-failure-by-50-versus-DPP-4-inhibitors-and-by-30-versus-GLP-1-receptor-agonists-in-adults-with-type-2-diabetes-in-real-world-evidence-study,2022-06-05,Clinical trial update
Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo,https://lilly.mediaroom.com/2022-06-04-Lillys-AWARD-PEDS-trial-investigating-use-of-Trulicity-R-dulaglutide-in-youth-and-adolescents-with-type-2-diabetes-showed-superiority-in-A1C-reduction-vs-placebo,2022-06-04,Clinical trial update
Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight,https://lilly.mediaroom.com/2022-06-04-Lillys-SURMOUNT-1-results-published-in-The-New-England-Journal-of-Medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight,2022-06-04,Clinical trial update
Lilly to Participate in Goldman Sachs Global Healthcare Conference,https://lilly.mediaroom.com/2022-06-03-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference,2022-06-03,Management update
Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://lilly.mediaroom.com/2022-05-26-Lilly-Announces-Details-of-Presentations-at-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting,2022-05-26,Clinical trial update
Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana,https://lilly.mediaroom.com/2022-05-25-Lilly-plans-to-invest-2-1-billion-in-new-manufacturing-sites-in-Indiana,2022-05-25,Management update
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study,https://lilly.mediaroom.com/2022-05-24-Fifty-Percent-of-Patients-with-Ulcerative-Colitis-Treated-with-Mirikizumab-Achieved-Clinical-Remission-at-One-Year-in-Lillys-Pivotal-Phase-3-Study,2022-05-24,Clinical trial update
Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA,https://lilly.mediaroom.com/2022-05-23-Lilly-Announces-Webcast-to-Provide-Diabetes-and-Obesity-Portfolio-Update-at-ADA,2022-05-23,Management update
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA),https://lilly.mediaroom.com/2022-05-20-CHMP-Recommends-Approval-of-Lilly-and-Incytes-OLUMIANT-R-baricitinib-as-the-First-and-Only-Centrally-Authorized-Treatment-for-Adults-with-Severe-Alopecia-Areata-AA,2022-05-20,Regulatory approval
Lilly to Participate in UBS Global Healthcare Conference 2022,https://lilly.mediaroom.com/2022-05-16-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference-2022,2022-05-16,Management update
"FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes","https://lilly.mediaroom.com/2022-05-13-FDA-approves-Lillys-Mounjaro-TM-tirzepatide-injection,-the-first-and-only-GIP-and-GLP-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes",2022-05-13,Regulatory approval
Mary Lynne Hedley Elected to Lilly Board of Directors,https://lilly.mediaroom.com/2022-05-06-Mary-Lynne-Hedley-Elected-to-Lilly-Board-of-Directors,2022-05-06,Management update
Lilly to Participate in Bank of America Securities 2022 Healthcare Conference,https://lilly.mediaroom.com/2022-05-03-Lilly-to-Participate-in-Bank-of-America-Securities-2022-Healthcare-Conference,2022-05-03,Management update
Lilly Declares Second-Quarter 2022 Dividend,https://lilly.mediaroom.com/2022-05-02-Lilly-Declares-Second-Quarter-2022-Dividend,2022-05-02,Financial news
Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022,https://lilly.mediaroom.com/2022-04-28-Solid-First-Quarter-Financial-Results-Reflect-Lillys-Continued-Momentum-into-2022,2022-04-28,Financial news
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1,https://lilly.mediaroom.com/2022-04-28-Lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-SURMOUNT-1,2022-04-28,Clinical trial update
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care,https://lilly.mediaroom.com/2022-04-20-Tackling-Health-Disparities-and-Inequities-for-Women-with-Heart-Failure-New-Program-Encourages-Black-and-Latina-Women-to-Demand-More-From-Their-Care,2022-04-20,Management update
Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement,https://lilly.mediaroom.com/2022-04-19-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2022-Financial-Results-Announcement,2022-04-19,Financial news
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis,https://lilly.mediaroom.com/2022-04-11-Lillys-Lebrikizumab-Combined-with-Topical-Corticosteroids-Showed-Significant-Improvements-in-Disease-Severity-for-Atopic-Dermatitis,2022-04-11,Clinical trial update
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress,https://lilly.mediaroom.com/2022-04-01-Lilly-Presents-Updated-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-NSCLC-at-the-2022-European-Lung-Cancer-Congress,2022-04-01,Clinical trial update
Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies,https://lilly.mediaroom.com/2022-03-26-Nearly-40-of-Adults-with-Alopecia-Areata-Taking-OLUMIANT-R-4-mg-Saw-at-Least-80-Scalp-Hair-Coverage-at-52-Weeks-in-Lillys-Pivotal-Phase-3-Studies,2022-03-26,Clinical trial update
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies,https://lilly.mediaroom.com/2022-03-26-Majority-of-Patients-Treated-with-Lebrikizumab-Achieved-Skin-Clearance-in-Lillys-Pivotal-Phase-3-Atopic-Dermatitis-Studies,2022-03-26,Clinical trial update
Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/2022-03-24-Lilly-Announces-Complete-Response-Letter-for-Sintilimab-in-Combination-with-Pemetrexed-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-People-with-Nonsquamous-Non-Small-Cell-Lung-Cancer,2022-03-24,Regulatory approval
Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease,https://lilly.mediaroom.com/2022-03-16-Jardiance-R-phase-III-EMPA-KIDNEY-trial-will-stop-early-due-to-clear-positive-efficacy-in-people-with-chronic-kidney-disease,2022-03-16,Clinical trial update
Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR),https://lilly.mediaroom.com/2022-03-08-Lilly-Announces-Details-of-Presentations-at-2022-American-Association-for-Cancer-Research-AACR,2022-03-08,Clinical trial update
Lilly to Participate in Barclays Global Healthcare Conference,https://lilly.mediaroom.com/2022-03-03-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference,2022-03-03,Management update
Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial,https://lilly.mediaroom.com/2022-03-01-Jardiance-R-provided-a-significant-clinical-benefit-in-adults-stabilized-in-hospital-following-acute-heart-failure-in-EMPULSE-phase-III-trial,2022-03-01,Clinical trial update
Lilly to Participate in Cowen Health Care Conference,https://lilly.mediaroom.com/2022-02-28-Lilly-to-Participate-in-Cowen-Health-Care-Conference,2022-02-28,Management update
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction,https://lilly.mediaroom.com/2022-02-24-US-FDA-approves-Jardiance-R-empagliflozin-to-treat-adults-with-heart-failure-regardless-of-left-ventricular-ejection-fraction,2022-02-24,Regulatory approval
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site,https://lilly.mediaroom.com/2022-02-22-Lilly-Announces-the-Institute-for-Genetic-Medicine-and-700-Million-investment-in-Boston-Seaport-Site,2022-02-22,Management update
Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study,https://lilly.mediaroom.com/2022-02-18-Nearly-Two-Thirds-of-Patients-Respond-to-Mirikizumab-Treatment-at-12-Weeks-in-Lillys-First-in-Class-Ulcerative-Colitis-Phase-3-LUCENT-1-Study,2022-02-18,Clinical trial update
Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence,https://lilly.mediaroom.com/2022-02-16-Lilly-and-Breast-Cancer-Advocacy-Organizations-Collaborate-to-Drive-Awareness-of-the-Complexities-of-Early-Breast-Cancer-and-the-Risk-of-Recurrence,2022-02-16,Management update
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19,https://lilly.mediaroom.com/2022-02-11-Lillys-bebtelovimab-receives-Emergency-Use-Authorization-for-the-treatment-of-mild-to-moderate-COVID-19,2022-02-11,Regulatory approval
"Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options","https://lilly.mediaroom.com/2022-02-10-Lilly-will-supply-up-to-600,000-doses-of-bebtelovimab-to-U-S-government-in-ongoing-effort-to-provide-COVID-19-treatment-options",2022-02-10,Commercialized drug update
Cynthia Cardona Elected as President of the Lilly Foundation,https://lilly.mediaroom.com/2022-02-10-Cynthia-Cardona-Elected-as-President-of-the-Lilly-Foundation,2022-02-10,Management update
"Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients","https://lilly.mediaroom.com/2022-02-03-Lilly-Reports-Solid-Fourth-Quarter-and-Full-Year-2021-Financial-Results,-Recent-Late-Stage-Pipeline-Successes-Set-Up-Next-Wave-of-Innovative-Medicines-for-Patients",2022-02-03,Financial news
UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents,https://lilly.mediaroom.com/2022-02-02-UNICEF-and-Lilly-Collaborate-to-Help-Improve-Health-Outcomes-for-10-Million-Children-and-Adolescents,2022-02-02,Management update
Lilly to Participate in Guggenheim Oncology Conference,https://lilly.mediaroom.com/2022-02-01-Lilly-to-Participate-in-Guggenheim-Oncology-Conference,2022-02-01,Management update
Lilly announces $1 billion investment in new manufacturing facility in North Carolina,https://lilly.mediaroom.com/2022-01-28-Lilly-announces-1-billion-investment-in-new-manufacturing-facility-in-North-Carolina,2022-01-28,Management update
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis,https://lilly.mediaroom.com/2022-01-28-Updates-on-OLUMIANT-R-baricitinib-Phase-3-lupus-program-and-FDA-review-for-atopic-dermatitis,2022-01-28,Clinical trial update
Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement,https://lilly.mediaroom.com/2022-01-20-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Announcement,2022-01-20,Financial news
Lilly to Participate in the J.P. Morgan Healthcare Conference,https://lilly.mediaroom.com/2022-01-06-Lilly-to-Participate-in-the-J-P-Morgan-Healthcare-Conference,2022-01-06,Management update
Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications,https://lilly.mediaroom.com/2022-01-06-Lilly-and-Entos-Pharmaceuticals-Enter-into-Research-and-Collaboration-Agreement-to-Support-the-Development-of-Innovative-Therapies-in-Multiple-Neurologic-Indications,2022-01-06T00:00:00,research collaboration
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study,https://lilly.mediaroom.com/2021-12-21-Lillys-lebrikizumab-demonstrated-significant-skin-improvement-and-itch-relief-when-combined-with-topical-corticosteroids-in-people-with-atopic-dermatitis-in-third-Phase-3-study,2021-12-21T00:00:00,clinical trial update
Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting,https://lilly.mediaroom.com/2021-12-15-Lilly-Highlights-Innovation-based-Growth-Strategy-and-Pipeline-Developments-Announces-2022-Financial-Guidance-at-Investment-Community-Meeting,2021-12-15T00:00:00,financial news
"Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022","https://lilly.mediaroom.com/2021-12-14-Mirikizumab-Demonstrates-Superiority-over-Placebo-in-Phase-3-Maintenance-Study-in-Ulcerative-Colitis,-Supporting-Regulatory-Submissions-in-2022",2021-12-14T00:00:00,clinical trial update
"Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend","https://lilly.mediaroom.com/2021-12-13-Lilly-Announces-15-Percent-Dividend-Increase,-First-Quarter-2022-Dividend",2021-12-13T00:00:00,financial news
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform,https://lilly.mediaroom.com/2021-12-13-Lilly-and-Foghorn-Announce-Strategic-Collaboration-for-Novel-Oncology-Targets-Using-Foghorns-Proprietary-Gene-Traffic-Control-R-Platform,2021-12-13T00:00:00,research collaboration
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting,https://lilly.mediaroom.com/2021-12-12-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-Pirtobrutinib-at-the-American-Society-of-Hematology-Annual-Meeting,2021-12-12T00:00:00,clinical trial update
Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders,https://lilly.mediaroom.com/2021-12-10-Lilly-and-Regor-Therapeutics-Group-Enter-into-Strategic-Collaboration-to-Discover-and-Develop-Novel-Therapies-for-Metabolic-Disorders,2021-12-10T00:00:00,research collaboration
New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients,https://lilly.mediaroom.com/2021-12-09-New-Lilly-Study-Reveals-Underappreciation-of-Bowel-Urgency-as-a-Symptom-of-Ulcerative-Colitis-and-Highlights-Communication-Gap-Between-Healthcare-Providers-and-Patients,2021-12-09T00:00:00,clinical trial update
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12,https://lilly.mediaroom.com/2021-12-03-Lillys-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-COVID-19-patients-under-the-age-of-12,2021-12-03T00:00:00,regulatory approval
Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting,https://lilly.mediaroom.com/2021-12-01-Lilly-to-Announce-Initial-2022-Financial-Guidance-Provide-R-D-Overview-at-Investment-Community-Meeting,2021-12-01T00:00:00,financial news
Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients,https://lilly.mediaroom.com/2021-11-18-Emgality-R-Versus-Nurtec-R-ODT-Head-to-Head-Migraine-Preventive-Treatment-Study-Now-Enrolling-Patients,2021-11-18T00:00:00,clinical trial update
Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference,https://lilly.mediaroom.com/2021-11-17-Lilly-to-Participate-in-Fourth-Annual-Evercore-ISI-HealthCONx-Conference,2021-11-17T00:00:00,management update
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction,https://lilly.mediaroom.com/2021-11-11-US-FDA-accepts-supplemental-New-Drug-Application-and-grants-Priority-Review-for-Jardiance-R-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction,2021-11-11T00:00:00,regulatory approval
"Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care","https://lilly.mediaroom.com/2021-11-11-Lilly-announces-winners-of-inaugural-Leonard-Award,-a-global-program-celebrating-100-years-of-innovation-in-diabetes-care",2021-11-11T00:00:00,management update
Lilly to Participate in Wolfe Research Virtual Healthcare Conference,https://lilly.mediaroom.com/2021-11-09-Lilly-to-Participate-in-Wolfe-Research-Virtual-Healthcare-Conference,2021-11-09T00:00:00,management update
"OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis","https://lilly.mediaroom.com/2021-11-09-OLUMIANT-R-Long-Term-Safety-Profile-Established-Up-to-9-3-Years-in-Integrated-Analysis-of-More-Than-3,700-Patients-with-Rheumatoid-Arthritis",2021-11-09T00:00:00,clinical trial update
Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status,https://lilly.mediaroom.com/2021-11-05-Jardiance-R-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-regardless-of-chronic-kidney-disease-status,2021-11-05T00:00:00,clinical trial update
Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting,https://lilly.mediaroom.com/2021-11-04-Loxo-Oncology-at-Lilly-Announces-Details-of-Presentations-at-the-2021-American-Society-of-Hematology-ASH-Annual-Meeting,2021-11-04T00:00:00,clinical trial update
"Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19","https://lilly.mediaroom.com/2021-11-02-Lilly-to-supply-614,000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-U-S-Government-for-the-treatment-or-post-exposure-prevention-of-COVID-19",2021-11-02T00:00:00,commercialized drug update
Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference,https://lilly.mediaroom.com/2021-11-01-Lilly-to-Participate-in-Bernsteins-Second-Annual-Operational-Decisions-Conference,2021-11-01T00:00:00,management update
Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology,https://lilly.mediaroom.com/2021-10-28-Additional-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Data-Published-in-the-Annals-of-Oncology,2021-10-28T00:00:00,clinical trial update
Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential,https://lilly.mediaroom.com/2021-10-26-Lilly-Reports-Robust-Third-Quarter-2021-Financial-Results-as-Pipeline-Success-Strengthens-Future-Growth-Potential,2021-10-26T00:00:00,financial news
Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk,https://lilly.mediaroom.com/2021-10-19-Tirzepatide-results-published-in-The-Lancet-show-superior-A1C-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk,2021-10-19T00:00:00,clinical trial update
Lilly Declares Fourth-Quarter 2021 Dividend,https://lilly.mediaroom.com/2021-10-18-Lilly-Declares-Fourth-Quarter-2021-Dividend,2021-10-18T00:00:00,financial news
Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology,https://lilly.mediaroom.com/2021-10-14-Lilly-Announces-Updated-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Data-Presented-at-ESMO-Virtual-Plenary-and-Simultaneously-Published-in-the-Annals-of-Oncology,2021-10-14T00:00:00,clinical trial update
FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer,https://lilly.mediaroom.com/2021-10-13-FDA-Approves-Verzenio-R-abemaciclib-as-the-First-and-Only-CDK4-6-Inhibitor-for-Certain-People-with-HR-HER2-High-Risk-Early-Breast-Cancer,2021-10-13T00:00:00,regulatory approval
Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement,https://lilly.mediaroom.com/2021-10-12-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2021-Financial-Results-Announcement,2021-10-12T00:00:00,financial news
Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics,https://lilly.mediaroom.com/2021-10-07-Loxo-Oncology-at-Lilly-Announces-Details-of-Presentations-at-2021-AACR-NCI-EORTC-Virtual-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics,2021-10-07T00:00:00,clinical trial update
Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals,https://lilly.mediaroom.com/2021-10-04-Ready-for-the-Challenge-Boehringer-Ingelheim-and-Eli-Lilly-and-Company-Launch-First-Ever-Online-Game-on-Cardio-Renal-Metabolic-Conditions-for-Healthcare-Professionals,2021-10-04T00:00:00,management update
"At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study","https://lilly.mediaroom.com/2021-10-01-At-Week-104,-75-of-Patients-with-Ulcerative-Colitis-Taking-Mirikizumab-Maintained-Symptomatic-Remission-in-Phase-2-Study",2021-10-01T00:00:00,clinical trial update
OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata,https://lilly.mediaroom.com/2021-09-30-OLUMIANT-R-Significantly-Improved-Hair-Regrowth-to-At-Least-80-Scalp-Coverage-as-Early-as-24-Weeks-Across-First-Completed-Phase-3-Studies-for-Alopecia-Areata,2021-09-30T00:00:00,clinical trial update
Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study,https://lilly.mediaroom.com/2021-09-30-Lillys-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-SURPASS-3-MRI-sub-study,2021-09-30T00:00:00,clinical trial update
Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study,https://lilly.mediaroom.com/2021-09-30-Lillys-tirzepatide-led-to-greater-time-in-range-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-SURPASS-3-CGM-sub-study,2021-09-30T00:00:00,clinical trial update
Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women,https://lilly.mediaroom.com/2021-09-29-Lilly-and-Susan-G-Komen-R-Partner-to-Address-Disparities-in-Breast-Cancer-Outcomes-Experienced-By-Black-Women,2021-09-29T00:00:00,management update
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy,https://lilly.mediaroom.com/2021-09-28-FDA-Expands-Lillys-ERBITUX-R-cetuximab-Label-with-Combination-of-BRAFTOVI-R-encorafenib-for-the-Treatment-of-BRAF-V600E-Mutation-Positive-Metastatic-Colorectal-Cancer-CRC-after-Prior-Therapy,2021-09-28T00:00:00,regulatory approval
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options,https://lilly.mediaroom.com/2021-09-28-Lilly-again-reduces-list-price-of-Insulin-Lispro-Injection-as-latest-change-to-affordability-options,2021-09-28T00:00:00,commercialized drug update
New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary,https://lilly.mediaroom.com/2021-09-27-New-Data-from-Verzenio-R-abemaciclib-monarchE-Study-to-Be-Featured-in-ESMO-Virtual-Plenary,2021-09-27T00:00:00,clinical trial update
Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency,https://lilly.mediaroom.com/2021-09-24-Eli-Lilly-and-Company-Issues-Voluntary-Nationwide-Recall-of-One-Lot-of-GLUCAGON-R-Emergency-Kit-Due-to-Loss-of-Potency,2021-09-24T00:00:00,commercialized drug update
Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities,https://lilly.mediaroom.com/2021-09-21-Lilly-Announces-the-Pricing-Terms-of-Its-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities,2021-09-21T00:00:00,financial news
Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19,https://lilly.mediaroom.com/2021-09-21-Lilly-announces-procurement-agreement-with-European-Commission-to-supply-bamlanivimab-and-etesevimab-together-for-the-treatment-of-confirmed-COVID-19,2021-09-21T00:00:00,commercialized drug update
Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059,https://lilly.mediaroom.com/2021-09-21-Lilly-Announces-the-Early-Tender-Results-of-Its-Pending-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities-and-Removal-of-the-Note-Caps-for-Its-3-950-Notes-due-2049-and-Its-4-150-Notes,2021-09-21T00:00:00,financial news
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19,https://lilly.mediaroom.com/2021-09-16-Emergency-Use-Authorization-for-Lillys-bamlanivimab-and-etesevimab-administered-together-expanded-to-include-post-exposure-prophylaxis-for-COVID-19,2021-09-16T00:00:00,regulatory approval
"Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19","https://lilly.mediaroom.com/2021-09-15-Lilly-to-supply-388,000-doses-of-etesevimab-to-U-S-government-for-treatment-of-COVID-19",2021-09-15T00:00:00,commercialized drug update
Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference,https://lilly.mediaroom.com/2021-09-13-Lilly-to-Participate-in-the-2021-Cantor-Virtual-Global-Healthcare-Conference,2021-09-13T00:00:00,management update
Lilly to Present New Data from Oncology Portfolio at ESMO Congress,https://lilly.mediaroom.com/2021-09-13-Lilly-to-Present-New-Data-from-Oncology-Portfolio-at-ESMO-Congress,2021-09-13T00:00:00,clinical trial update
Lilly Prices First Sustainability Bond to Advance Global ESG Strategy,https://lilly.mediaroom.com/2021-09-09-Lilly-Prices-First-Sustainability-Bond-to-Advance-Global-ESG-Strategy,2021-09-09T00:00:00,financial news
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction,https://lilly.mediaroom.com/2021-09-09-FDA-grants-Jardiance-R-Breakthrough-Therapy-designation-for-heart-failure-with-preserved-ejection-fraction,2021-09-09T00:00:00,regulatory approval
"Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to ""Type 1 Diabetes Camps Initiative""",https://lilly.mediaroom.com/2021-09-07-Lilly-Diabetes-joins-The-Leona-M-and-Harry-B-Helmsley-Charitable-Trust-to-pledge-significant-funding-to-Type-1-Diabetes-Camps-Initiative,2021-09-07T00:00:00,management update
Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities,https://lilly.mediaroom.com/2021-09-07-Lilly-Announces-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities,2021-09-07T00:00:00,financial news
Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference,https://lilly.mediaroom.com/2021-09-03-Lilly-to-Participate-in-the-Morgan-Stanley-19th-Annual-Global-Healthcare-Conference,2021-09-03,Financial news
Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference,https://lilly.mediaroom.com/2021-08-31-Lilly-to-Participate-in-Citis-16th-Annual-BioPharma-Virtual-Conference,2021-08-31,Financial news
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction,https://lilly.mediaroom.com/2021-08-27-Landmark-trial-demonstrates-Jardiance-R-empagliflozin-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction,2021-08-27,Clinical trial update
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders,https://lilly.mediaroom.com/2021-08-25-Lilly-and-Lycia-Therapeutics-Enter-into-Strategic-Collaboration-to-Discover-and-Develop-Novel-Lysosomal-Targeting-Chimera-LYTAC-Degraders,2021-08-25,Management update
Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors,https://lilly.mediaroom.com/2021-08-25-Lilly-Announces-that-Professor-Carolyn-Bertozzi-has-Resigned-from-its-Board-of-Directors,2021-08-25,Management update
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction,https://lilly.mediaroom.com/2021-08-18-US-FDA-approves-Jardiance-R-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction,2021-08-18,Regulatory approval
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units,https://lilly.mediaroom.com/2021-08-17-Lilly-Announces-Leadership-Changes-and-Formation-of-Neuroscience-and-Immunology-Business-Units,2021-08-17,Management update
FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps,https://lilly.mediaroom.com/2021-08-16-FDA-approves-Lyumjev-R-insulin-lispro-aabc-injection-100-units-mL-for-use-in-insulin-pumps,2021-08-16,Regulatory approval
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials,https://lilly.mediaroom.com/2021-08-16-Lillys-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-in-two-Phase-3-trials,2021-08-16,Clinical trial update
"Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance","https://lilly.mediaroom.com/2021-08-03-Lilly-Delivers-Strong-Second-Quarter-2021-Financial-Results,-Updates-2021-Financial-Guidance",2021-08-03,Financial news
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation,https://lilly.mediaroom.com/2021-08-03-Lilly-and-Incytes-baricitinib-reduced-deaths-among-patients-with-COVID-19-receiving-invasive-mechanical-ventilation,2021-08-03,Clinical trial update
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline,https://lilly.mediaroom.com/2021-07-29-Lilly-releases-donanemab-data-that-demonstrated-relationship-between-reduction-of-amyloid-plaque-and-slowing-of-cognitive-decline,2021-07-29,Clinical trial update
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen,https://lilly.mediaroom.com/2021-07-29-FDA-broadens-existing-emergency-use-of-Lilly-and-Incytes-baricitinib-in-patients-hospitalized-with-COVID-19-requiring-oxygen,2021-07-29,Regulatory approval
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses,https://lilly.mediaroom.com/2021-07-29-Lilly-and-Kumquat-Biosciences-Announce-Collaboration-to-Discover-and-Develop-Novel-Small-Molecules-that-Stimulate-Tumor-Specific-Immune-Responses,2021-07-29,Management update
Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement,https://lilly.mediaroom.com/2021-07-22-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2021-Financial-Results-Announcement,2021-07-22,Financial news
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis,https://lilly.mediaroom.com/2021-07-16-Lilly-and-Incyte-provide-update-on-supplemental-New-Drug-Application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis,2021-07-16,Regulatory approval
Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab,https://lilly.mediaroom.com/2021-07-15-Lilly-and-Banner-Alzheimers-Institute-collaborate-on-planned-Phase-3-prevention-trial-of-donanemab,2021-07-15,Clinical trial update
Lilly Announces Acquisition of Protomer Technologies,https://lilly.mediaroom.com/2021-07-14-Lilly-Announces-Acquisition-of-Protomer-Technologies,2021-07-14,Management update
Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study,https://lilly.mediaroom.com/2021-07-09-Mirikizumab-Up-Regulates-Genes-Associated-with-Mucosal-Healing-in-Ulcerative-Colitis-for-Up-to-One-Year-in-Phase-2-Study,2021-07-09,Clinical trial update
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction,https://lilly.mediaroom.com/2021-07-06-Breakthrough-results-for-Jardiance-R-empagliflozin-confirm-EMPEROR-Preserved-as-first-and-only-successful-trial-for-heart-failure-with-preserved-ejection-fraction,2021-07-06,Clinical trial update
Lilly Declares Third-Quarter 2021 Dividend,https://lilly.mediaroom.com/2021-06-29-Lilly-Declares-Third-Quarter-2021-Dividend,2021-06-29,Financial news
Lillys' SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes,https://lilly.mediaroom.com/2021-06-26-Lillys-SURPASS-1-results-published-in-The-Lancet-show-tirzepatides-superior-A1C-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes,2021-06-26,Clinical trial update
Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes,https://lilly.mediaroom.com/2021-06-25-Lillys-SURPASS-2-results-published-in-The-New-England-Journal-of-Medicine-show-tirzepatide-achieved-superior-A1C-and-body-weight-reductions-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes,2021-06-25,Clinical trial update
Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin,https://lilly.mediaroom.com/2021-06-24-Lilly-announces-call-for-Leonard-Award-nominations-as-part-of-global-initiative-celebrating-100-years-of-insulin,2021-06-24,Management update
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease,https://lilly.mediaroom.com/2021-06-24-Lillys-donanemab-receives-U-S-FDAs-Breakthrough-Therapy-designation-for-treatment-of-Alzheimers-disease,2021-06-24,Regulatory approval
Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine,https://lilly.mediaroom.com/2021-06-17-Lilly-Launches-Think-Talk-Treat-Migraine-TM-to-Help-Improve-Diagnosis-and-Treatment-of-Migraine,2021-06-17,Commercialized drug update
Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine,https://lilly.mediaroom.com/2021-06-15-Lilly-Announces-Head-to-Head-Study-Comparing-Once-Monthly-Emgality-R-with-Every-Other-Day-Nurtec-R-ODT-for-the-Preventive-Treatment-of-Migraine,2021-06-15,Clinical trial update
Lilly to Participate in Guggenheim Biopharma Strategy Series,https://lilly.mediaroom.com/2021-06-14-Lilly-to-Participate-in-Guggenheim-Biopharma-Strategy-Series,2021-06-14,Financial news
Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA,https://lilly.mediaroom.com/2021-06-11-Lilly-Announces-Webcast-to-Provide-Diabetes-Portfolio-Update-at-ADA,2021-06-11,Financial news
Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting,https://lilly.mediaroom.com/2021-06-04-Lilly-Announces-New-Clinical-Data-from-Verzenio-and-Oral-SERD-Programs-at-the-American-Society-of-Clinical-Oncology-Annual-Meeting,2021-06-04,Clinical trial update
Lilly to Participate in Goldman Sachs Healthcare Conference,https://lilly.mediaroom.com/2021-06-03-Lilly-to-Participate-in-Goldman-Sachs-Healthcare-Conference,2021-06-03,Financial news
"Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021","https://lilly.mediaroom.com/2021-06-03-Lilly-Reveals-Critical-Barriers-to-Optimal-Migraine-Care-and-Insights-From-Novel-Clinical-and-Patient-Centric-Real-World-Evidence,-Supporting-Lillys-Preventive-and-Acute-Treatment-Portfolio-at-AHS-2021",2021-06-03,Commercialized drug update
"OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses","https://lilly.mediaroom.com/2021-06-01-OLUMIANT-R-Improved-Pain,-Physical-Function-and-Morning-Joint-Stiffness-in-Rheumatoid-Arthritis-in-Phase-3-Post-Hoc-Analyses",2021-06-01,Clinical trial update
"Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study","https://lilly.mediaroom.com/2021-06-01-Taltz-R-Showed-Consistent,-Long-Term-Improvement-in-Key-Signs-and-Symptoms-of-Axial-Spondyloarthritis-Through-Two-Years-in-Phase-3-Study",2021-06-01,Clinical trial update
Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial,https://lilly.mediaroom.com/2021-05-22-Mirikizumab-Improves-Fatigue-in-Patients-with-Crohns-Disease-in-Phase-2-Trial,2021-05-22,Clinical trial update
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial,https://lilly.mediaroom.com/2021-05-20-Lillys-tirzepatide-achieves-all-primary-and-key-secondary-study-outcomes-against-insulin-glargine-in-adults-with-type-2-diabetes-and-increased-cardiovascular-risk-in-SURPASS-4-trial,2021-05-20,Clinical trial update
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting,https://lilly.mediaroom.com/2021-05-19-Lilly-Announces-Details-of-Presentations-at-2021-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting,2021-05-19,Clinical trial update
U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/index.php?s=9042&item=138226,2021-05-18,Regulatory approval
Lilly to Participate in UBS Global Healthcare Virtual Conference,https://lilly.mediaroom.com/2021-05-13-Lilly-to-Participate-in-UBS-Global-Healthcare-Virtual-Conference,2021-05-13,Financial news
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration,https://lilly.mediaroom.com/2021-05-11-Lilly-and-MiNA-Therapeutics-Announce-saRNA-Research-Collaboration,2021-05-11,Management update
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes,https://lilly.mediaroom.com/2021-05-06-Lilly-collaborates-internationally-with-leading-diabetes-technology-companies-to-integrate-connected-insulin-pen-solutions-for-people-with-diabetes,2021-05-06,Commercialized drug update
Lilly to Participate in Bank of America Securities 2021 Health Care Conference,https://lilly.mediaroom.com/2021-05-05-Lilly-to-Participate-in-Bank-of-America-Securities-2021-Health-Care-Conference,2021-05-05,Financial news
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries,https://lilly.mediaroom.com/2021-05-04-Lilly-plans-donation-of-COVID-19-therapies-to-Direct-Relief-for-use-in-low-and-lower-middle-income-countries,2021-05-04,Commercialized drug update
Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe,https://lilly.mediaroom.com/2021-05-04-Lilly-Outlines-Robust-Plans-to-Strengthen-ESG-Commitments-Across-the-Globe,2021-05-04,Management update
Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements,https://lilly.mediaroom.com/2021-05-04-Lilly-accelerating-baricitinibs-availability-in-India-following-receipt-of-permission-for-restricted-emergency-use-as-a-COVID-19-therapy-via-donations-and-licensing-agreements,2021-05-04,Commercialized drug update
Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization,https://lilly.mediaroom.com/2021-05-03-Lilly-Declares-Second-Quarter-2021-Dividend-and-Announces-Additional-Share-Repurchase-Authorization,2021-05-03,Financial news
Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity,https://lilly.mediaroom.com/2021-05-03-Lilly-to-Commit-5-Million-to-Direct-Reliefs-Fund-for-Health-Equity,2021-05-03,Management update
"Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance","https://lilly.mediaroom.com/2021-04-27-Lilly-Delivers-First-Quarter-2021-Financial-Results,-Adjusts-2021-Financial-Guidance",2021-04-27,Financial news
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses,https://lilly.mediaroom.com/2021-04-23-OLUMIANT-R-Showed-Significant-Improvements-in-the-Severity-and-Extent-of-Atopic-Dermatitis-and-Other-Patient-Reported-Outcomes-in-Phase-3-Study-Analyses,2021-04-23,Clinical trial update
Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis,https://lilly.mediaroom.com/2021-04-23-Taltz-R-Delivers-More-Cumulative-Days-with-Completely-Clear-Skin-for-Adults-with-Psoriasis-Compared-to-Seven-Other-Biologics-in-Novel-Network-Meta-Analysis,2021-04-23,Clinical trial update
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study,https://lilly.mediaroom.com/2021-04-20-Lilly-and-Incytes-Baricitinib-Improved-Hair-Regrowth-for-Alopecia-Areata-Patients-in-Second-Phase-3-Study,2021-04-20,clinical trial update
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.,https://lilly.mediaroom.com/2021-04-16-Lilly-requests-revocation-of-emergency-use-authorization-for-bamlanivimab-alone-to-complete-transition-to-bamlanivimab-and-etesevimab-together-for-treatment-of-COVID-19-in-the-U-S,2021-04-16,regulatory approval
Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer,https://lilly.mediaroom.com/2021-04-13-Diogo-Rau-to-join-Lilly-as-Senior-Vice-President-and-Chief-Information-and-Digital-Officer,2021-04-13,management update
Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together,https://lilly.mediaroom.com/2021-04-12-Lilly-modified-COVID-19-purchase-agreement-for-bamlanivimab-alone-with-the-U-S-government-and-is-focusing-on-supply-of-bamlanivimab-and-etesevimab-together,2021-04-12,commercialized drug update
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting,https://lilly.mediaroom.com/2021-04-11-Lilly-Presents-New-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Gastrointestinal-and-Other-Cancers-at-2021-American-Association-for-Cancer-Research-AACR-Annual-Meeting,2021-04-11,clinical trial update
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients,https://lilly.mediaroom.com/2021-04-08-Lilly-and-Incyte-announce-results-from-the-Phase-3-COV-BARRIER-study-of-baricitinib-in-hospitalized-COVID-19-patients,2021-04-08,clinical trial update
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis,https://lilly.mediaroom.com/2021-04-06-Lilly-and-Incyte-communicate-review-extension-of-supplemental-New-Drug-Application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis,2021-04-06,regulatory approval
Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement,https://lilly.mediaroom.com/2021-04-06-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2021-Financial-Results-Announcement,2021-04-06,financial news
"Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts",https://lilly.mediaroom.com/2021-04-01-Lilly-to-Host-Sustainability-Webcast-to-Provide-Overview-of-Environmental-Social-and-Governance-ESG-Efforts,2021-04-01,corporate social responsibility
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care,https://lilly.mediaroom.com/2021-03-31-Survey-reveals-healthcare-professionals-believe-greater-collaboration-is-needed-to-improve-patient-outcomes-in-diabetes-care,2021-03-31,commercialized drug update
"Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19",https://lilly.mediaroom.com/2021-03-29-Lilly-Vir-Biotechnology-and-GSK-Announce-Positive-Topline-Data-from-the-Phase-2-BLAZE-4-Trial-Evaluating-Bamlanivimab-with-VIR-7831-in-Low-Risk-Adults-with-COVID-19,2021-03-29,clinical trial update
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain,https://lilly.mediaroom.com/index.php?s=9042&item=138180,2021-03-25,regulatory approval
Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021,https://lilly.mediaroom.com/2021-03-17-Lilly-Presents-Patient-Reported-Outcomes-from-the-Positive-Phase-3-monarchE-Trial-for-Verzenio-R-at-St-Gallen-Virtual-Congress-2021,2021-03-17,clinical trial update
Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study,https://lilly.mediaroom.com/2021-03-16-Lillys-Mirikizumab-Helps-Patients-Achieve-Clinical-Remission-and-Improves-Symptoms-in-Adults-with-Ulcerative-Colitis-in-12-Week-Phase-3-Induction-Study,2021-03-16,clinical trial update
Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM,https://lilly.mediaroom.com/2021-03-13-Lillys-donanemab-slowed-Alzheimers-disease-progression-in-Phase-2-trial-full-data-presented-at-AD-PD-TM-2021-and-published-in-NEJM,2021-03-13,clinical trial update
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR),https://lilly.mediaroom.com/2021-03-10-Lilly-Announces-Details-of-Presentations-at-2021-American-Association-for-Cancer-Research-AACR,2021-03-10,clinical trial update
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19,https://lilly.mediaroom.com/2021-03-10-Lillys-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-Phase-3-trial-for-early-COVID-19,2021-03-10,clinical trial update
Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research,https://lilly.mediaroom.com/2021-03-09-Data-from-Lilly-at-International-Conference-on-Alzheimers-Parkinson-Diseases-2021-TM-AD-PD-TM-2021-to-Showcase-Clinical-Advances-in-Alzheimers-Disease-Research,2021-03-09,clinical trial update
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations,https://lilly.mediaroom.com/2021-03-09-Lilly-Announces-Leadership-Transitions-in-Manufacturing-and-Ethics-and-Compliance-Organizations,2021-03-09,management update
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes,https://lilly.mediaroom.com/2021-03-08-Lilly-and-Biolojic-Design-Announce-Research-Collaboration-to-Discover-and-Develop-Antibody-Therapies-for-Diabetes,2021-03-08,research collaboration
Lilly to Participate in Barclays Global Healthcare Conference,https://lilly.mediaroom.com/2021-03-08-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference,2021-03-08,financial news
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union,https://lilly.mediaroom.com/2021-03-05-EMA-issues-advice-on-Lillys-bamlanivimab-LY-CoV555-alone-and-administered-together-with-etesevimab-LY-CoV016-for-the-treatment-of-confirmed-COVID-19-in-the-European-Union,2021-03-05,regulatory approval
Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet,https://lilly.mediaroom.com/2021-03-05-Loxo-Oncology-at-Lilly-Announces-Publication-of-Pirtobrutinib-LOXO-305-Phase-1-2-Data-in-The-Lancet,2021-03-05,clinical trial update
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes,https://lilly.mediaroom.com/2021-03-04-Tirzepatide-achieved-superior-A1C-and-body-weight-reductions-across-all-three-doses-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes,2021-03-04,clinical trial update
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial,https://lilly.mediaroom.com/2021-03-03-Baricitinib-is-First-JAK-Inhibitor-to-Demonstrate-Hair-Regrowth-in-Phase-3-Alopecia-Areata-AA-Trial,2021-03-03,clinical trial update
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19,https://lilly.mediaroom.com/2021-02-26-Lilly-announces-additional-doses-of-neutralizing-antibody-therapy-purchased-by-U-S-government-to-treat-COVID-19,2021-02-26,commercialized drug update
Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions,https://lilly.mediaroom.com/2021-02-25-Welldoc-and-Lilly-collaborate-to-integrate-BlueStar-R-app-capabilities-into-Lillys-connected-insulin-solutions,2021-02-25,commercialized drug update
Lilly to Participate in Cowen Health Care Conference,https://lilly.mediaroom.com/2021-02-24-Lilly-to-Participate-in-Cowen-Health-Care-Conference,2021-02-24,financial news
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases,https://lilly.mediaroom.com/2021-02-18-Lilly-and-Rigel-Enter-Strategic-Collaboration-to-Develop-RIPK1-Inhibitors-for-the-Potential-Treatment-of-Immunological-and-Neurodegenerative-Diseases,2021-02-18,research collaboration
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program,https://lilly.mediaroom.com/2021-02-17-Tirzepatide-significantly-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes-in-two-phase-3-trials-from-Lillys-SURPASS-program,2021-02-17,clinical trial update
Kimberly H. Johnson Elected to Lilly Board of Directors,https://lilly.mediaroom.com/2021-02-17-Kimberly-H-Johnson-Elected-to-Lilly-Board-of-Directors,2021-02-17,management update
Lilly To Participate in SVB Leerink Global Healthcare Conference,https://lilly.mediaroom.com/2021-02-11-Lilly-To-Participate-in-SVB-Leerink-Global-Healthcare-Conference,2021-02-11,financial news
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19,https://lilly.mediaroom.com/2021-02-09-Lillys-bamlanivimab-LY-CoV555-administered-with-etesevimab-LY-CoV016-receives-FDA-emergency-use-authorization-for-COVID-19,2021-02-09,regulatory approval
Lilly Appoints Anat Ashkenazi Chief Financial Officer,https://lilly.mediaroom.com/2021-02-09-Lilly-Appoints-Anat-Ashkenazi-Chief-Financial-Officer,2021-02-09,management update
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference,https://lilly.mediaroom.com/2021-02-04-Lilly-Announces-Webcast-to-Provide-Alzheimers-Disease-Update-at-AD-PD-Conference,2021-02-04,clinical trial update
Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day,https://lilly.mediaroom.com/2021-02-03-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-2021-Oncology-Day,2021-02-03,financial news
Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients,https://lilly.mediaroom.com/2021-02-01-Lilly-Partners-with-Area-Health-Systems-to-Help-Enable-Access-to-Important-Antibody-Infusion-Therapies-for-COVID-19-Patients,2021-02-01,commercialized drug update
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results,https://lilly.mediaroom.com/2021-01-29-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2020-Financial-Results,2021-01-29,financial news
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate,https://lilly.mediaroom.com/2021-01-28-Lilly-and-Asahi-Kasei-Pharma-Announce-License-Agreement-for-Chronic-Pain-Drug-Candidate,2021-01-28,research collaboration
"Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19",https://lilly.mediaroom.com/2021-01-27-Lilly-Vir-Biotechnology-and-GSK-announce-first-patient-dosed-in-expanded-BLAZE-4-trial-evaluating-bamlanivimab-LY-CoV555-with-VIR-7831-GSK4182136-for-COVID-19,2021-01-27,clinical trial update
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death  by 70 percent,https://lilly.mediaroom.com/2021-01-26-New-data-show-treatment-with-Lillys-neutralizing-antibodies-bamlanivimab-LY-CoV555-and-etesevimab-LY-CoV016-together-reduced-risk-of-COVID-19-hospitalizations-and-death-by-70-percent,2021-01-26,clinical trial update
Lilly Completes Acquisition of Prevail Therapeutics,https://lilly.mediaroom.com/2021-01-22-Lilly-Completes-Acquisition-of-Prevail-Therapeutics,2021-01-22,management update
"Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents",https://lilly.mediaroom.com/2021-01-21-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-prevented-COVID-19-at-nursing-homes-in-the-BLAZE-2-trial-reducing-risk-by-up-to-80-percent-for-residents,2021-01-21,clinical trial update
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies,https://lilly.mediaroom.com/2021-01-19-Lilly-and-Merus-NV-Announce-Collaboration-to-Discover-Novel-T-Cell-Re-Directing-Bispecific-Antibodies,2021-01-19,research collaboration
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement,https://lilly.mediaroom.com/2021-01-15-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2020-Financial-Results-Announcement,2021-01-15,financial news
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund,https://lilly.mediaroom.com/2021-01-15-Lilly-Announces-30-Million-Limited-Partner-Investment-in-Unseen-Capital-Health-Fund,2021-01-15,financial news
Gabrielle Sulzberger Elected to Lilly Board of Directors,https://lilly.mediaroom.com/2021-01-14-Gabrielle-Sulzberger-Elected-to-Lilly-Board-of-Directors,2021-01-14,management update
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction,https://lilly.mediaroom.com/2021-01-11-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-empagliflozin-for-adults-with-heart-failure-with-reduced-ejection-fraction,2021-01-11,regulatory approval
Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial,https://lilly.mediaroom.com/2021-01-11-Lillys-Donanemab-Slows-Clinical-Decline-of-Alzheimers-Disease-in-Positive-Phase-2-Trial,2021-01-11,clinical trial update
Lilly to Participate in J.P. Morgan Healthcare Conference,https://lilly.mediaroom.com/2021-01-04-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference,2021-01-04,financial news
Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico,https://lilly.mediaroom.com/2020-12-18-Lilly-to-begin-pragmatic-study-of-neutralizing-antibody-bamlanivimab-LY-CoV555-for-COVID-19-in-New-Mexico,2020-12-18T00:00:00,clinical trial update
"Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance",https://lilly.mediaroom.com/2020-12-15-Lilly-Announces-2021-Financial-Guidance-Updates-2020-Guidance,2020-12-15T00:00:00,financial news
Lilly Announces Agreement to Acquire Prevail Therapeutics,https://lilly.mediaroom.com/2020-12-15-Lilly-Announces-Agreement-to-Acquire-Prevail-Therapeutics,2020-12-15T00:00:00,management update
Lilly Announces 15 Percent Dividend Increase,https://lilly.mediaroom.com/2020-12-14-Lilly-Announces-15-Percent-Dividend-Increase,2020-12-14T00:00:00,financial news
Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study,https://lilly.mediaroom.com/2020-12-14-Lilly-announces-opening-of-patient-enrollment-for-New-IDEAS-Imaging-Dementia-Evidence-for-Amyloid-Scanning-study,2020-12-14T00:00:00,clinical trial update
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine,https://lilly.mediaroom.com/2020-12-11-Data-from-ACTT-2-Trial-of-Baricitinib-in-Hospitalized-COVID-19-Patients-Supportive-of-the-EUA-Published-in-New-England-Journal-of-Medicine,2020-12-11T00:00:00,clinical trial update
Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®,https://lilly.mediaroom.com/2020-12-09-Lilly-Presents-Positive-Primary-Outcome-Data-from-monarchE-that-Builds-on-Previous-Definitive-Analysis-for-Verzenio-R,2020-12-09T00:00:00,clinical trial update
Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes,https://lilly.mediaroom.com/2020-12-09-Lillys-tirzepatide-significantly-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes,2020-12-09T00:00:00,clinical trial update
Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement,https://lilly.mediaroom.com/2020-12-08-Lilly-Confirms-Date-and-Conference-Call-for-2021-Financial-Guidance-Announcement,2020-12-08T00:00:00,financial news
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting,https://lilly.mediaroom.com/2020-12-07-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-LOXO-305-in-Chronic-Lymphocytic-Leukemia-and-Small-Lymphocytic-Lymphoma-at-the-American-Society-of-Hematology-Annual-Meeting,2020-12-07T00:00:00,clinical trial update
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting,https://lilly.mediaroom.com/2020-12-05-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-LOXO-305-in-Mantle-Cell-Lymphoma-and-Non-Hodgkin-Lymphomas-at-the-American-Society-of-Hematology-ASH-Annual-Meeting,2020-12-05T00:00:00,clinical trial update
Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19,https://lilly.mediaroom.com/2020-12-04-Lilly-and-UnitedHealth-Group-partner-on-pragmatic-study-of-neutralizing-antibody-bamlanivimab-LY-CoV555-for-COVID-19,2020-12-04T00:00:00,clinical trial update
"Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19",https://lilly.mediaroom.com/2020-12-02-Lilly-announces-650-000-additional-doses-of-neutralizing-antibody-bamlanivimab-LY-CoV555-purchased-by-U-S-government-to-treat-COVID-19,2020-12-02T00:00:00,commercialized drug update
Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference,https://lilly.mediaroom.com/2020-11-24-Lilly-to-Participate-in-Evercore-ISI-3rd-Annual-HealthCONx-Conference,2020-11-24T00:00:00,management update
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19,https://lilly.mediaroom.com/2020-11-20-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-receives-interim-authorization-from-Health-Canada-as-a-treatment-for-COVID-19,2020-11-20T00:00:00,regulatory approval
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement,https://lilly.mediaroom.com/2020-11-20-Lilly-and-Precision-BioSciences-Announce-Genome-Editing-Research-Collaboration-and-License-Agreement,2020-11-20T00:00:00,management update
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19,https://lilly.mediaroom.com/2020-11-19-Baricitinib-Receives-Emergency-Use-Authorization-from-the-FDA-for-the-Treatment-of-Hospitalized-Patients-with-COVID-19,2020-11-19T00:00:00,regulatory approval
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes,https://lilly.mediaroom.com/2020-11-19-Lilly-and-Ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes,2020-11-19T00:00:00,management update
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial,https://lilly.mediaroom.com/2020-11-18-Jardiance-R-reduced-the-risk-of-first-plus-recurrent-cardiovascular-events-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease-in-new-analysis-from-the-EMPA-REG-OUTCOME-R-trial,2020-11-18T00:00:00,clinical trial update
Lilly to Participate in Wolfe Research Virtual Healthcare Conference,https://lilly.mediaroom.com/2020-11-12-Lilly-to-Participate-in-Wolfe-Research-Virtual-Healthcare-Conference,2020-11-12T00:00:00,management update
Lilly to Participate in Bernstein Operational Decisions Conference,https://lilly.mediaroom.com/2020-11-12-Lilly-to-Participate-in-Bernstein-Operational-Decisions-Conference,2020-11-12T00:00:00,management update
Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program,https://lilly.mediaroom.com/2020-11-11-Lilly-Announces-Webcast-to-Provide-an-Overview-of-Tirzepatide-Phase-3-clinical-program,2020-11-11T00:00:00,clinical trial update
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19,https://lilly.mediaroom.com/2020-11-09-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-receives-FDA-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-COVID-19,2020-11-09T00:00:00,regulatory approval
Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting,https://lilly.mediaroom.com/2020-11-05-Loxo-Oncology-at-Lilly-Announces-Details-of-LOXO-305-Presentations-at-the-2020-American-Society-of-Hematology-ASH-Annual-Meeting,2020-11-05T00:00:00,clinical trial update
Aarti Shah to Retire as Lilly Chief Information and Digital Officer,https://lilly.mediaroom.com/2020-11-05-Aarti-Shah-to-Retire-as-Lilly-Chief-Information-and-Digital-Officer,2020-11-05T00:00:00,management update
ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis,https://lilly.mediaroom.com/2020-11-02-ACR-2020-Lilly-and-Incyte-Highlight-Positive-Data-for-Olumiant-R-in-Rheumatoid-Arthritis,2020-11-02T00:00:00,clinical trial update
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis,https://lilly.mediaroom.com/2020-10-31-EADV-2020-Lilly-and-Incyte-Showcase-New-Data-for-Baricitinib-for-the-Treatment-of-Moderate-to-Severe-Atopic-Dermatitis,2020-10-31T00:00:00,clinical trial update
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata,https://lilly.mediaroom.com/2020-10-30-Fall-Clinical-Dermatology-2020-Lilly-and-Incyte-Showcase-Positive-New-Data-for-Baricitinib-in-Adult-Patients-with-Alopecia-Areata,2020-10-30T00:00:00,clinical trial update
New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis,https://lilly.mediaroom.com/2020-10-29-New-Data-at-EADV-2020-Confirm-Taltz-R-ixekizumab-Demonstrates-Sustained-Long-Term-Efficacy-in-Patients-with-Psoriasis-and-Psoriatic-Arthritis,2020-10-29T00:00:00,clinical trial update
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine,https://lilly.mediaroom.com/2020-10-28-Data-for-Lillys-bamlanivimab-LY-CoV555-in-COVID-19-outpatients-published-in-New-England-Journal-of-Medicine,2020-10-28T00:00:00,clinical trial update
"Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19",https://lilly.mediaroom.com/2020-10-28-Lilly-announces-agreement-with-U-S-government-to-supply-300-000-vials-of-investigational-neutralizing-antibody-bamlanivimab-LY-CoV555-in-an-effort-to-fight-COVID-19,2020-10-28T00:00:00,COVID-19
"Lilly Reports Third-Quarter Financial Results, Updates Guidance",https://lilly.mediaroom.com/2020-10-27-Lilly-Reports-Third-Quarter-Financial-Results-Updates-Guidance,2020-10-27T00:00:00,financial news
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status,https://lilly.mediaroom.com/2020-10-23-New-Jardiance-R-findings-showed-improved-cardio-renal-outcomes-in-adults-with-heart-failure-with-reduced-ejection-fraction-regardless-of-chronic-kidney-disease-status,2020-10-23T00:00:00,clinical trial update
Lilly Declares Fourth-Quarter 2020 Dividend,https://lilly.mediaroom.com/2020-10-19-Lilly-Declares-Fourth-Quarter-2020-Dividend,2020-10-19T00:00:00,financial news
Lilly Announces Agreement to Acquire Disarm Therapeutics,https://lilly.mediaroom.com/2020-10-15-Lilly-Announces-Agreement-to-Acquire-Disarm-Therapeutics,2020-10-15T00:00:00,management update
Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial,https://lilly.mediaroom.com/2020-10-12-Mirikizumab-Shows-Continued-Symptom-Improvement-and-Reduction-of-Intestinal-Inflammation-in-Patients-with-Crohns-Disease-in-52-Week-Phase-2-Trial,2020-10-12T00:00:00,clinical trial update
Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment,https://lilly.mediaroom.com/2020-10-09-Lillys-OVERCOME-Study-Reveals-Nearly-80-of-People-Reported-Improvement-in-Their-Migraine-Since-Starting-a-CGRP-Monoclonal-Antibody-for-Preventive-Treatment,2020-10-09T00:00:00,clinical trial update
Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement,https://lilly.mediaroom.com/2020-10-08-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2020-Financial-Results-Announcement,2020-10-08T00:00:00,financial news
"Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen",https://lilly.mediaroom.com/2020-10-08-Baricitinib-has-Significant-Effect-on-Recovery-Time-Most-Impactful-in-COVID-19-Patients-Requiring-Oxygen,2020-10-08T00:00:00,clinical trial update
"Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity",https://lilly.mediaroom.com/2020-10-08-Indy-Racial-Equity-Pledge-Launches-to-Drive-Accountability-Action-and-Progress-on-Racial-Equity,2020-10-08T00:00:00,management update
Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries,https://lilly.mediaroom.com/2020-10-08-Lilly-Announces-Arrangement-for-Supply-of-Potential-COVID-19-Antibody-Therapy-for-Low-and-Middle-Income-Countries,2020-10-08T00:00:00,COVID-19
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs,https://lilly.mediaroom.com/2020-10-07-Lilly-provides-comprehensive-update-on-progress-of-SARS-CoV-2-neutralizing-antibody-programs,2020-10-07T00:00:00,clinical trial update
Lilly and Dexcom team up on new program to help improve diabetes management,https://lilly.mediaroom.com/2020-10-07-Lilly-and-Dexcom-team-up-on-new-program-to-help-improve-diabetes-management,2020-10-07T00:00:00,management update
REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study,https://lilly.mediaroom.com/2020-10-06-REYVOW-R-lasmiditan-C-V-Demonstrated-Superior-Pain-Freedom-At-2-Hours-in-At-Least-2-of-3-Migraine-Attacks-in-New-Phase-3-Consistency-of-Effect-Study,2020-10-06T00:00:00,clinical trial update
"Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer",https://lilly.mediaroom.com/2020-09-20-Verzenio-R-Significantly-Reduced-the-Risk-of-Cancer-Recurrence-by-25-for-People-with-HR-HER2-High-Risk-Early-Breast-Cancer,2020-09-20T00:00:00,clinical trial update
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis,https://lilly.mediaroom.com/2020-09-18-CHMP-Recommends-Approval-of-Lillys-Baricitinib-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Atopic-Dermatitis,2020-09-18T00:00:00,regulatory approval
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies,https://lilly.mediaroom.com/2020-09-17-Lilly-and-Amgen-Announce-Manufacturing-Collaboration-for-COVID-19-Antibody-Therapies,2020-09-17T00:00:00,management update
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting,https://lilly.mediaroom.com/2020-09-16-Lilly-announces-proof-of-concept-data-for-neutralizing-antibody-LY-CoV555-in-the-COVID-19-outpatient-setting,2020-09-16T00:00:00,clinical trial update
Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care,https://lilly.mediaroom.com/2020-09-15-Lilly-Launches-Digital-Health-Open-Innovation-Challenge-to-Help-Transform-Atopic-Dermatitis-Care,2020-09-15T00:00:00,management update
US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack,https://lilly.mediaroom.com/2020-09-15-US-FDA-grants-Fast-Track-designation-to-Jardiance-R-empagliflozin-to-improve-outcomes-following-a-heart-attack,2020-09-15T00:00:00,regulatory approval
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial,https://lilly.mediaroom.com/2020-09-14-Baricitinib-in-Combination-with-Remdesivir-Reduces-Time-to-Recovery-in-Hospitalized-Patients-with-COVID-19-in-NIAID-Sponsored-ACTT-2-Trial,2020-09-14T00:00:00,clinical trial update
Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference,https://lilly.mediaroom.com/2020-09-11-Lilly-to-Participate-in-Cantor-Fitzgerald-Virtual-Global-Healthcare-Conference,2020-09-11T00:00:00,financial news
Lilly to Participate in Morgan Stanley Global Healthcare Conference,https://lilly.mediaroom.com/2020-09-11-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference,2020-09-11T00:00:00,financial news
REYVOW® (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study,https://lilly.mediaroom.com/2020-09-11-REYVOW-TM-lasmiditan-C-V-Demonstrated-Pain-Freedom-from-Migraine-Attacks-At-60-Minutes-and-Up-to-48-Hours-in-New-Phase-3-Study,2020-09-11T00:00:00,clinical trial update
Lilly Announces Webcast to Discuss ESMO 2020 Presentations,https://lilly.mediaroom.com/2020-09-10-Lilly-Announces-Webcast-to-Discuss-ESMO-2020-Presentations,2020-09-10T00:00:00,financial news
"Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes",https://lilly.mediaroom.com/2020-09-10-Lilly-commits-Insulin-Value-Program-featuring-35-copay-card-to-suite-of-affordability-solutions-for-people-with-diabetes,2020-09-10T00:00:00,commercialized drug update
Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020,https://lilly.mediaroom.com/2020-09-10-Lilly-Oncology-to-Showcase-New-Data-from-Robust-Cancer-Research-Pipeline-at-ESMO-Virtual-Congress-2020,2020-09-10T00:00:00,clinical trial update
Lilly Announces Leadership Changes,https://lilly.mediaroom.com/2020-09-09-Lilly-Announces-Leadership-Changes,2020-09-09T00:00:00,management update
FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes,https://lilly.mediaroom.com/2020-09-03-FDA-approves-additional-doses-of-Trulicity-R-dulaglutide-for-the-treatment-of-type-2-diabetes,2020-09-03T00:00:00,regulatory approval
Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction,https://lilly.mediaroom.com/2020-08-29-Jardiance-R-reduced-the-combined-relative-risk-of-cardiovascular-death-and-hospitalization-for-heart-failure-by-25-in-adults-with-and-without-diabetes-who-had-heart-failure-with-reduced-ejection-fraction,2020-08-29T00:00:00,clinical trial update
New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers,https://lilly.mediaroom.com/2020-08-27-New-England-Journal-of-Medicine-Publishes-Phase-1-2-Data-for-Retevmo-TM-selpercatinib-in-Advanced-RET-Driven-Lung-and-Thyroid-Cancers,2020-08-27T00:00:00,clinical trial update
Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement,https://lilly.mediaroom.com/2020-08-18-Lilly-and-Innovent-Announce-Global-Expansion-of-TYVYT-Licensing-Agreement,2020-08-18T00:00:00,commercialized drug update
Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID),https://lilly.mediaroom.com/2020-08-03-Lilly-Initiates-Phase-3-Trial-of-LY-CoV555-for-Prevention-of-COVID-19-at-Long-Term-Care-Facilities-in-Partnership-with-the-National-Institute-of-Allergy-and-Infectious-Diseases-NIAID,2020-08-03T00:00:00,clinical trial update
"Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance",https://lilly.mediaroom.com/2020-07-30-Lilly-Reports-Second-Quarter-Financial-Results-Raises-EPS-Guidance,2020-07-30T00:00:00,financial news
Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes,https://lilly.mediaroom.com/2020-07-30-Jardiance-R-meets-primary-endpoint-in-reducing-risk-of-cardiovascular-death-or-hospitalization-for-heart-failure-in-phase-III-trial-in-adults-with-and-without-diabetes,2020-07-30T00:00:00,clinical trial update
Lilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA,https://lilly.mediaroom.com/2020-07-28-Lillys-P-tau217-Blood-Test-Shows-High-Accuracy-in-Diagnosis-of-Alzheimers-Disease-in-Data-Published-in-JAMA,2020-07-28T00:00:00,clinical trial update
Data from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research,https://lilly.mediaroom.com/2020-07-21-Data-from-Lilly-at-Alzheimers-Association-International-Conference-2020-R-AAIC-R-2020-to-Showcase-Clinical-Advances-in-Alzheimers-Research,2020-07-21T00:00:00,clinical trial update
Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement,https://lilly.mediaroom.com/2020-07-17-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2020-Financial-Results-Announcement,2020-07-17T00:00:00,financial news
Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis,https://lilly.mediaroom.com/2020-07-17-Lillys-Mirikizumab-Superior-to-Cosentyx-R-secukinumab-in-a-Phase-3-Study-for-Patients-with-Moderate-to-Severe-Plaque-Psoriasis,2020-07-17T00:00:00,clinical trial update
Lilly Declares Third-Quarter 2020 Dividend,https://lilly.mediaroom.com/2020-07-15-Lilly-Declares-Third-Quarter-2020-Dividend,2020-07-15T00:00:00,financial news
Central Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments,https://lilly.mediaroom.com/2020-06-25-Central-Indiana-Racial-Equity-Fund-Launches-with-more-than-2-2-Million-in-Initial-Commitments,2020-06-25T00:00:00,corporate social responsibility
Lilly launches program about what people with diabetes should “Know Before the Low”,https://lilly.mediaroom.com/2020-06-24-Lilly-launches-program-about-what-people-with-diabetes-should-Know-Before-the-Low,2020-06-24T00:00:00,commercialized drug update
Full results from EMPERIAL exercise ability trials presented,https://lilly.mediaroom.com/2020-06-19-Full-results-from-EMPERIAL-exercise-ability-trials-presented,2020-06-19T00:00:00,clinical trial update
"Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine",https://lilly.mediaroom.com/2020-06-17-Emgality-R-Demonstrates-Reduction-in-Frequency-Duration-and-Pain-Severity-in-Patients-with-Episodic-and-Chronic-Migraine,2020-06-17T00:00:00,clinical trial update
Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications,https://lilly.mediaroom.com/2020-06-16-Lillys-OVERCOME-Study-Reveals-Less-than-30-Percent-of-People-Living-with-Migraine-Take-Recommended-Prescription-Medications,2020-06-16T00:00:00,clinical trial update
"Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer",https://lilly.mediaroom.com/2020-06-16-Verzenio-R-abemaciclib-Significantly-Reduced-the-Risk-of-Cancer-Returning-in-People-with-High-Risk-HR-HER2-Early-Breast-Cancer,2020-06-16T00:00:00,clinical trial update
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients,https://lilly.mediaroom.com/2020-06-15-Lilly-Begins-a-Phase-3-Clinical-Trial-with-Baricitinib-for-Hospitalized-COVID-19-Patients,2020-06-15T00:00:00,clinical trial update
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections,https://lilly.mediaroom.com/2020-06-13-Once-weekly-Trulicity-R-dulaglutide-demonstrates-significantly-higher-adherence-and-more-persistence-compared-to-once-weekly-semaglutide-and-exenatide-injections,2020-06-13T00:00:00,clinical trial update
Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice,https://lilly.mediaroom.com/2020-06-13-Eli-Lilly-and-Company-Foundation-Pledges-25-Million-to-Combat-Racial-Injustice,2020-06-13T00:00:00,corporate social responsibility
"Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life",https://lilly.mediaroom.com/2020-06-12-Lilly-and-Dermira-Present-New-Lebrikizumab-Phase-2b-Clinical-Data-Showing-Patients-with-Atopic-Dermatitis-Had-Clinically-Meaningful-Improvements-in-Itch-Sleep-and-Quality-of-Life,2020-06-12T00:00:00,clinical trial update
Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD),https://lilly.mediaroom.com/2020-06-12-Lilly-Highlights-the-Evolution-of-Its-Dermatology-Portfolio-at-Annual-American-Academy-of-Dermatology-Meeting-AAD,2020-06-12T00:00:00,commercialized drug update
"Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event",https://lilly.mediaroom.com/2020-06-12-Lilly-Partners-with-Indianapolis-Recorder-Newspaper-Radio-One-and-WISH-TV-for-a-Day-of-Solidarity-Virtual-Event,2020-06-12T00:00:00,corporate social responsibility
First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial,https://lilly.mediaroom.com/2020-06-09-First-patient-dose-delivered-for-Lillys-tirzepatide-cardiovascular-outcomes-trial,2020-06-09T00:00:00,clinical trial update
Lilly to Participate in Goldman Sachs Global Healthcare Conference,https://lilly.mediaroom.com/2020-06-08-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference,2020-06-08T00:00:00,financial news
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment,https://lilly.mediaroom.com/2020-06-08-Lilly-Announces-Start-of-a-Phase-1-Study-for-its-Second-Potential-COVID-19-Antibody-Treatment,2020-06-08T00:00:00,clinical trial update
EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus,https://lilly.mediaroom.com/2020-06-03-EULAR-2020-Lilly-Shares-New-Data-for-Olumiant-R-in-Rheumatoid-Arthritis-and-Systemic-Lupus-Erythematosus,2020-06-03T00:00:00,clinical trial update
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis,https://lilly.mediaroom.com/2020-06-03-EULAR-2020-Lillys-Taltz-R-ixekizumab-Continues-to-Show-Robust-and-Consistent-Efficacy-in-Psoriatic-Arthritis,2020-06-03T00:00:00,clinical trial update
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA),https://lilly.mediaroom.com/2020-06-01-Lillys-Taltz-R-ixekizumab-is-the-First-IL-17A-Antagonist-to-Receive-U-S-FDA-Approval-for-the-Treatment-of-Non-Radiographic-Axial-Spondyloarthritis-nr-axSpA,2020-06-01T00:00:00,regulatory approval
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans,https://lilly.mediaroom.com/2020-06-01-Lilly-Begins-Worlds-First-Study-of-a-Potential-COVID-19-Antibody-Treatment-in-Humans,2020-06-01T00:00:00,clinical trial update
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/2020-05-29-Lillys-CYRAMZA-R-ramucirumab-Receives-FDA-Approval-as-First-Line-Treatment-for-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer,2020-05-29T00:00:00,regulatory approval
Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease,https://lilly.mediaroom.com/2020-05-28-Lilly-Receives-U-S-FDA-Approval-of-TAUVID-TM-flortaucipir-F-18-injection-for-Use-in-Patients-Being-Evaluated-for-Alzheimers-Disease,2020-05-28T00:00:00,regulatory approval
Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model,https://lilly.mediaroom.com/2020-05-26-Statement-from-Lilly-Chairman-and-CEO-Dave-Ricks-on-New-Part-D-Senior-Savings-Model,2020-05-26T00:00:00,financial news
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction,https://lilly.mediaroom.com/2020-05-26-Boehringer-Ingelheim-and-Lilly-to-collaborate-with-Duke-Clinical-Research-Institute-on-a-pragmatic-trial-examining-Jardiances-R-effects-following-an-acute-myocardial-infarction,2020-05-26T00:00:00,clinical trial update
Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure,https://lilly.mediaroom.com/2020-05-26-Emgality-R-Shows-Improvement-in-Work-Productivity-and-Health-and-Well-Being-Between-Attacks-in-Patients-with-Migraine-and-a-History-of-Preventive-Treatment-Failure,2020-05-26T00:00:00,clinical trial update
Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease,https://lilly.mediaroom.com/2020-05-19-Results-of-GERAS-US-Study-Demonstrate-Societal-Cost-Burden-for-Patients-and-Caregivers-During-Early-Stages-of-Alzheimers-Disease,2020-05-19T00:00:00,clinical trial update
Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020,https://lilly.mediaroom.com/2020-05-13-Lilly-Oncology-Showcases-Innovation-in-Cancer-Research-at-ASCO-2020,2020-05-13T00:00:00,clinical trial update
"Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers",https://lilly.mediaroom.com/2020-05-08-Lilly-Receives-U-S-FDA-Approval-for-Retevmo-TM-selpercatinib-the-First-Therapy-Specifically-for-Patients-with-Advanced-RET-Driven-Lung-and-Thyroid-Cancers,2020-05-08T00:00:00,regulatory approval
Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes,https://lilly.mediaroom.com/2020-05-08-Higher-investigational-doses-of-Trulicity-R-dulaglutide-meaningfully-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes,2020-05-08T00:00:00,clinical trial update
Lilly to Participate in UBS Virtual Global Healthcare Conference,https://lilly.mediaroom.com/2020-05-05-Lilly-to-Participate-in-UBS-Virtual-Global-Healthcare-Conference,2020-05-05T00:00:00,financial news
Lilly Declares Second-Quarter 2020 Dividend,https://lilly.mediaroom.com/2020-05-04-Lilly-Declares-Second-Quarter-2020-Dividend,2020-05-04T00:00:00,financial news
Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19,https://lilly.mediaroom.com/2020-05-04-Lilly-and-Junshi-Biosciences-to-Co-develop-Antibody-Therapies-for-the-Prevention-and-Treatment-of-COVID-19,2020-05-04,Collaboration
Lilly to Participate in Bank of America Securities Health Care Conference,https://lilly.mediaroom.com/2020-04-30-Lilly-to-Participate-in-Bank-of-America-Securities-Health-Care-Conference,2020-04-30,Financial news
"Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance",https://lilly.mediaroom.com/2020-04-23-Lilly-Reports-Strong-First-Quarter-Financial-Results-Adjusts-EPS-Guidance,2020-04-23,Financial news
Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available,https://lilly.mediaroom.com/2020-04-16-Lower-priced-versions-of-Humalog-R-Mix75-25-TM-KwikPen-R-and-Humalog-R-Junior-KwikPen-R-now-available,2020-04-16,Commercialized drug update
Lilly Begins Clinical Testing of Therapies for COVID-19,https://lilly.mediaroom.com/2020-04-10-Lilly-Begins-Clinical-Testing-of-Therapies-for-COVID-19,2020-04-10,Clinical trial update
Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement,https://lilly.mediaroom.com/2020-04-08-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2020-Financial-Results-Announcement,2020-04-08,Financial news
Eli Lilly and Company to Hold 2020 Annual Meeting of Shareholders Virtually,https://lilly.mediaroom.com/2020-04-07-Eli-Lilly-and-Company-to-Hold-2020-Annual-Meeting-of-Shareholders-Virtually,2020-04-07,Management update
New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.,https://lilly.mediaroom.com/2020-04-07-New-35-Co-Pay-Now-Available-Through-Lilly-Insulin-Value-Program-in-Response-to-COVID-19-Crisis-in-U-S,2020-04-07,Commercialized drug update
"Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic",https://lilly.mediaroom.com/2020-04-01-Medical-Professionals-Across-Merck-Co-Inc-Pfizer-Inc-and-Eli-Lilly-and-Company-Activate-to-Support-Health-Systems-First-Responders-and-Patients-Amid-COVID-19-Pandemic,2020-04-01,Collaboration
"Governor Holcomb and Mayor Hogsett announce coalition to flatten the COVID-19 curve across state, public invited to make commitment",https://lilly.mediaroom.com/2020-04-01-Governor-Holcomb-and-Mayor-Hogsett-announce-coalition-to-flatten-the-COVID-19-curve-across-state-public-invited-to-make-commitment,2020-04-01,Collaboration
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines,https://lilly.mediaroom.com/2020-03-31-Lilly-and-Sitryx-Announce-Licensing-and-Research-Collaboration-to-Discover-and-Develop-New-Immunometabolic-Medicines,2020-03-31,Collaboration
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis,https://lilly.mediaroom.com/2020-03-30-Lillys-Taltz-R-ixekizumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Pediatric-Patients-with-Moderate-to-Severe-Plaque-Psoriasis,2020-03-30,Regulatory approval
Updates from Lilly about insulin supply and affordability,https://lilly.mediaroom.com/2020-03-24-Updates-from-Lilly-about-insulin-supply-and-affordability,2020-03-24,Commercialized drug update
Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic,https://lilly.mediaroom.com/2020-03-23-Lilly-Provides-Update-on-Clinical-Trial-Activities-During-COVID-19-Pandemic,2020-03-23,Clinical trial update
Lilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers,https://lilly.mediaroom.com/2020-03-22-Lilly-to-Provide-Drive-Through-COVID-19-Testing-for-Indianapolis-Health-Care-Workers,2020-03-22,Collaboration
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes,https://lilly.mediaroom.com/2020-03-20-US-FDA-issues-complete-response-letter-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes,2020-03-20,Regulatory approval
"Kathryn Beiser to join Lilly as Vice President, Global Communications",https://lilly.mediaroom.com/2020-03-20-Kathryn-Beiser-to-join-Lilly-as-Vice-President-Global-Communications,2020-03-20,Management update
"Lilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories",https://lilly.mediaroom.com/2020-03-18-Lilly-Indiana-State-Department-of-Health-Partner-to-Accelerate-COVID-19-Testing-Using-Lilly-Research-Laboratories,2020-03-18,Collaboration
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata,https://lilly.mediaroom.com/2020-03-16-Lilly-Receives-FDA-Breakthrough-Therapy-Designation-for-Baricitinib-for-the-Treatment-of-Alopecia-Areata,2020-03-16,Regulatory approval
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19,https://lilly.mediaroom.com/2020-03-12-AbCellera-and-Lilly-to-Co-develop-Antibody-Therapies-for-the-Treatment-of-COVID-19,2020-03-12,Collaboration
US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease,https://lilly.mediaroom.com/2020-03-12-US-FDA-grants-Fast-Track-designation-to-Jardiance-R-for-the-treatment-of-chronic-kidney-disease,2020-03-12,Regulatory approval
Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D,https://lilly.mediaroom.com/2020-03-11-Lilly-to-Participate-in-New-Model-Designed-to-Make-Insulins-More-Affordable-for-Seniors-in-Medicare-Part-D,2020-03-11,Commercialized drug update
Lilly to Participate in Barclays Global Healthcare Conference,https://lilly.mediaroom.com/2020-03-09-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference,2020-03-09,Financial news
Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines,https://lilly.mediaroom.com/2020-03-03-Lilly-Statement-on-Novel-Coronavirus-and-the-Reliable-Supply-of-the-Companys-Medicines,2020-03-03,Commercialized drug update
"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis",https://lilly.mediaroom.com/2020-03-02-U-S-FDA-Accepts-Regulatory-Submission-for-Tanezumab-a-Potential-First-in-Class-Treatment-for-Patients-with-Chronic-Pain-Due-to-Moderate-to-Severe-Osteoarthritis,2020-03-02,Regulatory approval
Eli Lilly and Company Statement on ICER Final Report for Acute Treatments for Migraine: Effectiveness and Value,https://lilly.mediaroom.com/2020-02-28-Eli-Lilly-and-Company-Statement-on-ICER-Final-Report-for-Acute-Treatments-for-Migraine-Effectiveness-and-Value,2020-02-28,Commercialized drug update
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/2020-02-26-FDA-Advisory-Committee-Votes-in-Favor-of-Lillys-CYRAMZA-R-ramucirumab-as-First-Line-Treatment-for-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer,2020-02-26,Regulatory approval
Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease,https://lilly.mediaroom.com/2020-02-21-Trulicity-R-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease,2020-02-21,Regulatory approval
Lilly to Participate in Cowen Health Care Conference,https://lilly.mediaroom.com/2020-02-21-Lilly-to-Participate-in-Cowen-Health-Care-Conference,2020-02-21,Financial news
Lilly To Participate in SVB Leerink Global Healthcare Conference,https://lilly.mediaroom.com/2020-02-21-Lilly-To-Participate-in-SVB-Leerink-Global-Healthcare-Conference,2020-02-21,Financial news
Lilly Completes Acquisition of Dermira,https://lilly.mediaroom.com/2020-02-20-Lilly-Completes-Acquisition-of-Dermira,2020-02-20,Management update
Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study,https://lilly.mediaroom.com/2020-02-10-Lilly-Announces-Topline-Results-for-Solanezumab-from-the-Dominantly-Inherited-Alzheimer-Network-Trials-Unit-DIAN-TU-Study,2020-02-10,Clinical trial update
Lilly to Participate in Guggenheim Healthcare Talks Idea Forum,https://lilly.mediaroom.com/2020-02-07-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-Idea-Forum,2020-02-07,Financial news
"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription",https://lilly.mediaroom.com/2020-01-31-Lillys-REYVOW-TM-lasmiditan-C-V-the-First-and-Only-Medicine-in-a-New-Class-of-Acute-Treatment-for-Migraine-ditan-Now-Available-for-Prescription,2020-01-31,Commercialized drug update
CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes,https://lilly.mediaroom.com/2020-01-31-CHMP-Recommends-Approval-of-Lillys-New-Fast-Acting-Mealtime-Insulin-to-Improve-Glycemic-Control-in-Adults-with-Diabetes,2020-01-31,Regulatory approval
"Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition",https://lilly.mediaroom.com/2020-01-30-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2019-Financial-Results-Updates-2020-Guidance-for-Pending-Dermira-Acquisition,2020-01-30,Financial news
Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis,https://lilly.mediaroom.com/2020-01-30-Lilly-and-Incyte-Announce-Positive-Top-Line-Results-from-the-North-American-BREEZE-AD5-Phase-3-Study-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis,2020-01-30,Clinical trial update
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application,https://lilly.mediaroom.com/2020-01-29-Lilly-Receives-FDA-Priority-Review-for-the-Selpercatinib-New-Drug-Application,2020-01-29,Regulatory approval
"Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities",https://lilly.mediaroom.com/2020-01-28-Lilly-plans-donation-of-200-000-insulin-KwikPens-over-next-three-years-to-support-lower-income-communities,2020-01-28,Commercialized drug update
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes,https://lilly.mediaroom.com/2020-01-27-US-FDA-approves-only-triple-combination-tablet-with-Jardiance-R-for-adults-with-type-2-diabetes,2020-01-27,Regulatory approval
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine,https://lilly.mediaroom.com/2020-01-27-Lilly-and-Incyte-Announce-Top-Line-Results-from-Phase-3-Study-BREEZE-AD4-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Combination-with-Topical-Corticosteroids-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis-Not-Controlled-with-Cyclospor,2020-01-27,Clinical trial update
Anat Hakim to join Lilly as General Counsel,https://lilly.mediaroom.com/2020-01-24-Anat-Hakim-to-join-Lilly-as-General-Counsel,2020-01-24,Management update
Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant,https://lilly.mediaroom.com/2020-01-21-Governor-Cooper-Announces-over-460-Jobs-in-Durham-as-Eli-Lilly-and-Company-Selects-North-Carolina-for-Major-Pharmaceutical-Plant,2020-01-21,Management update
Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement,https://lilly.mediaroom.com/2020-01-16-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2019-Financial-Results-Announcement,2020-01-16,Financial news
"Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease",https://lilly.mediaroom.com/2020-01-15-Lilly-Anna-Kaiser-Launch-30-Day-Thriver-Challenge-to-Increase-Awareness-of-Daily-Stress-of-Living-with-Metastatic-Breast-Cancer-Elevate-Support-for-Women-and-Men-Living-with-the-Disease,2020-01-15,Commercialized drug update
Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®,https://lilly.mediaroom.com/2020-01-14-Lilly-expands-insulin-affordability-options-with-lower-priced-versions-of-Humalog-R-Mix75-25-TM-KwikPen-R-and-Humalog-R-Junior-KwikPen-R,2020-01-14,Commercialized drug update
Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC,https://lilly.mediaroom.com/2020-01-13-Tyvyt-R-Sintilimab-Injection-Combined-with-ALIMTA-R-Pemetrexed-and-Platinum-Met-Predefined-Primary-Endpoint-in-Phase-3-ORIENT-11-Study-as-First-Line-Therapy-in-Nonsquamous-NSCLC,2020-01-13,Clinical trial update
Lilly Announces Agreement to Acquire Dermira,https://lilly.mediaroom.com/2020-01-10-Lilly-Announces-Agreement-to-Acquire-Dermira,2020-01-10,Management update
"Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab",https://lilly.mediaroom.com/2020-01-09-Eli-Lilly-and-Company-in-Collaboration-with-Strateos-Inc-Launch-Remote-Controlled-Robotic-Cloud-Lab,2020-01-09,Collaboration
Lilly to Participate in J.P. Morgan Healthcare Conference,https://lilly.mediaroom.com/2020-01-02-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference,2020-01-02,Financial news
U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit,https://lilly.mediaroom.com/2019-12-30-U-S-District-Court-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit,2019-12-30T00:00:00,Regulatory Approval
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer,https://lilly.mediaroom.com/2019-12-30-Lilly-Opens-Phase-3-Clinical-Trial-in-RET-Mutant-Medullary-Thyroid-Cancer,2019-12-30T00:00:00,Clinical Trial Update
Lilly Launches Campaign to Increase Awareness of Insulin Cost-Saving Options,https://lilly.mediaroom.com/2019-12-19-Lilly-Launches-Campaign-to-Increase-Awareness-of-Insulin-Cost-Saving-Options,2019-12-19T00:00:00,Commercialized Drug Update
"Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)",https://lilly.mediaroom.com/2019-12-18-Lilly-Announces-the-Launch-of-TRIUMPH-the-First-Long-Term-Real-World-Evidence-Study-of-Emgality-R-galcanezumab-gnlm,2019-12-18T00:00:00,Clinical Trial Update
"Lilly Announces 2020 Financial Guidance, Updates 2019 Guidance",https://lilly.mediaroom.com/2019-12-17-Lilly-Announces-2020-Financial-Guidance-Updates-2019-Guidance,2019-12-17T00:00:00,Financial News
Lilly Announces 15 Percent Dividend Increase,https://lilly.mediaroom.com/2019-12-16-Lilly-Announces-15-Percent-Dividend-Increase,2019-12-16T00:00:00,Financial News
Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System,https://lilly.mediaroom.com/2019-12-16-Lilly-to-Integrate-Dexcom-CGM-into-Personalized-Diabetes-Management-System,2019-12-16T00:00:00,Commercialized Drug Update
Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure,https://lilly.mediaroom.com/2019-12-13-Boehringer-Ingelheim-and-Lilly-provide-update-on-Jardiance-R-phase-III-exercise-ability-studies-in-chronic-heart-failure,2019-12-13T00:00:00,Clinical Trial Update
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/2019-12-13-CHMP-Issues-Positive-Opinion-to-Expand-CYRAMZA-R-ramucirumab-Label-to-Include-Results-from-RELAY-Study-in-Patients-with-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer,2019-12-13T00:00:00,Regulatory Approval
Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/2019-12-11-Lilly-Opens-First-Ever-Randomized-Phase-3-Clinical-Trial-in-Treatment-Naive-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer,2019-12-11T00:00:00,Clinical Trial Update
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting,https://lilly.mediaroom.com/2019-12-08-Lilly-Presents-Interim-Clinical-Data-from-LOXO-305-Dose-Escalation-Trial-in-B-Cell-Leukemias-and-Lymphomas-at-the-American-Society-Hematology-Annual-Meeting,2019-12-08T00:00:00,Clinical Trial Update
Lilly Announces New Leadership and Strategy in Oncology Research and Development,https://lilly.mediaroom.com/2019-12-05-Lilly-Announces-New-Leadership-and-Strategy-in-Oncology-Research-and-Development,2019-12-05T00:00:00,Management Update
Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference,https://lilly.mediaroom.com/2019-12-02-Lilly-to-Participate-in-Evercore-ISI-2nd-Annual-HealthCONx-Conference,2019-12-02T00:00:00,Financial News
Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco,https://lilly.mediaroom.com/2019-12-02-Eli-Lilly-and-Company-Unveils-Shared-Innovation-Laboratory-in-South-San-Francisco,2019-12-02T00:00:00,Management Update
Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD),https://lilly.mediaroom.com/2019-12-02-Lilly-Names-HealthVoyager-as-Winner-of-Digital-Health-Innovation-Challenge-for-Inflammatory-Bowel-Disease-IBD,2019-12-02T00:00:00,Commercialized Drug Update
Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis,https://lilly.mediaroom.com/2019-11-20-Lilly-announces-400-million-capital-investment-in-manufacturing-facilities-in-Indianapolis,2019-11-20T00:00:00,Financial News
Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement,https://lilly.mediaroom.com/2019-11-19-Lilly-Confirms-Date-and-Conference-Call-for-2020-Financial-Guidance-Announcement,2019-11-19T00:00:00,Financial News
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists,https://lilly.mediaroom.com/2019-11-17-Interim-analysis-from-EMPRISE-real-world-study-shows-Jardiance-R-decreased-risk-of-hospitalization-for-heart-failure-compared-with-DPP-4-inhibitors-and-GLP-1-receptor-agonists,2019-11-17T00:00:00,Clinical Trial Update
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes,https://lilly.mediaroom.com/2019-11-13-Boehringer-Ingelheim-and-Lilly-announce-outcome-of-FDA-Advisory-Committee-meeting-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes,2019-11-13T00:00:00,Regulatory Approval
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized,https://lilly.mediaroom.com/2019-11-12-Boehringer-Ingelheim-and-Lilly-initiate-first-ever-study-to-assess-Jardiance-R-in-people-hospitalized-for-acute-heart-failure-who-have-been-stabilized,2019-11-12T00:00:00,Clinical Trial Update
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis,https://lilly.mediaroom.com/2019-11-12-ACR-2019-Lilly-Presents-52-Week-Head-to-Head-SPIRIT-H2H-Data-from-Taltz-R-ixekizumab-Versus-Humira-R-adalimumab-Trial-in-Psoriatic-Arthritis,2019-11-12T00:00:00,Clinical Trial Update
"ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",https://lilly.mediaroom.com/2019-11-12-ACR-2019-Lilly-Presents-Positive-New-Data-from-COAST-X-a-Phase-3-Study-of-Taltz-R-ixekizumab-in-Patients-with-Non-Radiographic-Axial-Spondyloarthritis,2019-11-12T00:00:00,Clinical Trial Update
Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting,https://lilly.mediaroom.com/2019-11-08-Lilly-Reinforces-its-Commitment-to-Rheumatology-through-Data-Showcased-at-the-ACR-ARP-Annual-Meeting,2019-11-08T00:00:00,Clinical Trial Update
"Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities",https://lilly.mediaroom.com/2019-11-07-Lilly-Announces-the-Pricing-Terms-of-its-Cash-Tender-Offer-for-Up-to-2-000-006-000-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities,2019-11-07T00:00:00,Financial News
"Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities",https://lilly.mediaroom.com/2019-11-07-Lilly-Announces-the-Early-Tender-Results-and-Upsizing-of-Its-Pending-Cash-Tender-Offer-to-Up-to-2-000-006-000-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities,2019-11-07T00:00:00,Financial News
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019,https://lilly.mediaroom.com/2019-11-06-Eli-Lilly-and-Company-to-Present-Multiple-Abstracts-for-LOXO-305-at-ASH-2019,2019-11-06T00:00:00,Clinical Trial Update
Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference,https://lilly.mediaroom.com/2019-11-04-Lilly-to-Participate-in-Credit-Suisse-28th-Annual-Healthcare-Conference,2019-11-04T00:00:00,Financial News
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®,https://lilly.mediaroom.com/2019-11-04-Boehringer-Ingelheim-and-Lilly-modernise-alliance-to-focus-full-expertise-on-Jardiance-R,2019-11-04T00:00:00,Commercialized Drug Update
Lilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities,https://lilly.mediaroom.com/2019-10-24-Lilly-Announces-Cash-Tender-Offer-for-Up-to-2-0-Billion-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities,2019-10-24T00:00:00,Financial News
"Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance",https://lilly.mediaroom.com/2019-10-23-Lilly-Reports-Strong-Third-Quarter-2019-Financial-Results-Raises-2019-EPS-Guidance,2019-10-23T00:00:00,Financial News
"Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno",https://lilly.mediaroom.com/2019-10-23-Enrique-Conterno-Senior-Vice-President-and-President-of-Lilly-Diabetes-and-Lilly-USA-to-Retire-at-End-of-Year-Mike-Mason-to-Succeed-Conterno,2019-10-23T00:00:00,Management Update
Lilly Declares Fourth-Quarter 2019 Dividend,https://lilly.mediaroom.com/2019-10-21-Lilly-Declares-Fourth-Quarter-2019-Dividend,2019-10-21T00:00:00,Financial News
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival,https://lilly.mediaroom.com/2019-10-16-Lilly-Announces-Phase-3-Study-in-Patients-with-Metastatic-Pancreatic-Cancer-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival,2019-10-16T00:00:00,Clinical Trial Update
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress,https://lilly.mediaroom.com/2019-10-12-Lilly-Presents-Positive-Results-for-Taltz-R-ixekizumab-in-Pediatric-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-at-the-28th-Annual-European-Academy-of-Dermatology-and-Venereology-EADV-Congress,2019-10-12T00:00:00,Clinical Trial Update
"Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval",https://lilly.mediaroom.com/2019-10-11-Lillys-REYVOW-TM-lasmiditan-The-First-and-Only-Medicine-in-a-New-Class-of-Acute-Treatment-for-Migraine-Receives-FDA-Approval,2019-10-11T00:00:00,Regulatory Approval
Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress,https://lilly.mediaroom.com/2019-10-08-Lilly-to-Unveil-New-Data-for-the-Treatments-of-Complex-Dermatological-Conditions-at-the-28th-Annual-European-Academy-of-Dermatology-and-Venereology-EADV-Congress,2019-10-08T00:00:00,Clinical Trial Update
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology,https://lilly.mediaroom.com/2019-10-07-Lillys-CYRAMZA-R-ramucirumab-Phase-3-Data-in-First-Line-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-Published-in-The-Lancet-Oncology,2019-10-07T00:00:00,Clinical Trial Update
Lilly Announces Voluntary Delisting from Euronext Paris,https://lilly.mediaroom.com/2019-10-03-Lilly-Announces-Voluntary-Delisting-from-Euronext-Paris,2019-10-03T00:00:00,Financial News
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis,https://lilly.mediaroom.com/2019-10-03-New-Head-to-Head-Data-Show-Taltz-R-ixekizumab-Superiority-versus-TREMFYA-R-guselkumab-in-People-with-Moderate-to-Severe-Plaque-Psoriasis,2019-10-03T00:00:00,Clinical Trial Update
Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement,https://lilly.mediaroom.com/2019-10-02-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2019-Financial-Results-Announcement,2019-10-02T00:00:00,Financial News
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers,https://lilly.mediaroom.com/2019-09-29-Lilly-Announces-Positive-Registrational-Data-for-Selpercatinib-LOXO-292-in-Heavily-Pretreated-RET-Altered-Thyroid-Cancers,2019-09-29T00:00:00,Clinical Trial Update
Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019,https://lilly.mediaroom.com/2019-09-23-Lilly-Oncology-to-Present-Robust-Data-across-Its-Growing-Portfolio-at-ESMO-2019,2019-09-23T00:00:00,Clinical Trial Update
CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial,https://lilly.mediaroom.com/2019-09-20-CHMP-Issues-Positive-Opinion-to-Expand-Trulicity-R-dulaglutide-Label-to-Include-Results-from-REWIND-Cardiovascular-Outcomes-Trial,2019-09-20T00:00:00,Regulatory Approval
Lilly Announces Webcast to Discuss ESMO 2019 Presentations,https://lilly.mediaroom.com/2019-09-19-Lilly-Announces-Webcast-to-Discuss-ESMO-2019-Presentations,2019-09-19T00:00:00,Financial News
"Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",https://lilly.mediaroom.com/2019-09-09-Lilly-Announces-Positive-Results-for-Selpercatinib-LOXO-292-Demonstrating-a-68-Percent-Objective-Response-Rate-and-Sustained-Durability-in-Heavily-Pretreated-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer,2019-09-09T00:00:00,Clinical Trial Update
Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program,https://lilly.mediaroom.com/2019-09-05-Lillys-Pain-Clinical-Trial-Protocol-Selected-for-FDA-Complex-Innovative-Trial-Designs-Pilot-Meeting-Program,2019-09-05T00:00:00,Clinical Trial Update
Lilly to Participate in Morgan Stanley Global Healthcare Conference,https://lilly.mediaroom.com/2019-09-04-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference,2019-09-04T00:00:00,Financial News
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis),https://lilly.mediaroom.com/2019-08-26-Lilly-Receives-U-S-FDA-Approval-for-Taltz-R-ixekizumab-for-the-Treatment-of-Active-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis,2019-08-26T00:00:00,Regulatory Approval
"Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis",https://lilly.mediaroom.com/2019-08-23-Lilly-Announces-Top-Line-Phase-3-Results-for-Oral-JAK-Inhibitor-Baricitinib-in-Combination-with-Topical-Corticosteroids-in-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis,2019-08-23T00:00:00,Clinical Trial Update
Arbitration panel rules in favor of Lilly in complaint filed by Adocia,https://lilly.mediaroom.com/2019-08-22-Arbitration-panel-rules-in-favor-of-Lilly-in-complaint-filed-by-Adocia,2019-08-22T00:00:00,Legal News
Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation,https://lilly.mediaroom.com/2019-08-19-Lilly-Announces-Webcast-to-Discuss-World-Conference-on-Lung-Cancer-Presentation,2019-08-19T00:00:00,clinical trial update
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health,https://lilly.mediaroom.com/2019-08-14-Lilly-Launches-Open-Innovation-Challenge-to-Help-Transform-Inflammatory-Bowel-Disease-IBD-Care-through-Digital-Health,2019-08-14T00:00:00,clinical trial update
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis,https://lilly.mediaroom.com/2019-08-13-Lilly-Announces-Superiority-of-Taltz-R-ixekizumab-versus-TREMFYA-R-guselkumab-in-Delivering-Total-Skin-Clearance-at-Week-12-in-Topline-Results-from-Head-to-Head-IXORA-R-Trial-in-People-Living-with-Moderate-to-Severe-Plaque-Psoriasis,2019-08-13T00:00:00,clinical trial update
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit,https://lilly.mediaroom.com/2019-08-09-U-S-Court-of-Appeals-Rules-in-Favor-of-Lilly-in-Alimta-Alternate-Salt-Form-Patent-Lawsuit,2019-08-09T00:00:00,regulatory approval
"Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia",https://lilly.mediaroom.com/2019-08-08-Lilly-Evidation-Health-and-Apple-Study-Shows-Personal-Digital-Devices-May-Help-in-the-Identification-of-Mild-Cognitive-Impairment-and-Mild-Alzheimers-Disease-Dementia,2019-08-08T00:00:00,clinical trial update
"Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services",https://lilly.mediaroom.com/2019-08-07-Lilly-Announces-Leadership-Changes-in-Corporate-Business-Development-Oncology-R-D-and-Managed-Healthcare-Services,2019-08-07T00:00:00,management update
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments,https://lilly.mediaroom.com/2019-08-05-Lilly-Announces-Positive-Results-for-Emgality-R-galcanezumab-gnlm-from-the-CONQUER-Study-in-Patients-who-Failed-Previous-Migraine-Preventive-Treatments,2019-08-05T00:00:00,clinical trial update
"Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance",https://lilly.mediaroom.com/2019-07-30-Lilly-Reports-Second-Quarter-2019-Financial-Results-Raises-2019-EPS-Guidance,2019-07-30T00:00:00,financial news
"Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2",https://lilly.mediaroom.com/2019-07-30-Lillys-Verzenio-R-abemaciclib-Significantly-Extended-Life-in-Women-with-HR-HER2-Advanced-Breast-Cancer-in-MONARCH-2,2019-07-30T00:00:00,clinical trial update
"BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA",https://lilly.mediaroom.com/2019-07-24-BAQSIMI-TM-glucagon-Nasal-Powder-3-mg-the-First-and-Only-Nasally-Administered-Glucagon-to-Treat-Severe-Hypoglycemia-in-Adults-and-Children-with-Diabetes-Ages-Four-Years-and-Older-Approved-by-FDA,2019-07-24T00:00:00,regulatory approval
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study,https://lilly.mediaroom.com/2019-07-13-Lilly-Presents-New-Findings-on-Stigma-Faced-by-People-with-Migraine-Based-on-Interim-Results-from-the-OVERCOME-Observational-Study,2019-07-13T00:00:00,clinical trial update
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine,https://lilly.mediaroom.com/2019-07-12-Lillys-OVERCOME-Observational-Study-Reveals-Inconsistent-and-Sub-Optimal-Treatment-Landscape-for-Migraine,2019-07-12T00:00:00,clinical trial update
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine,https://lilly.mediaroom.com/2019-07-12-AHS-2019-Post-Hoc-Analyses-of-Phase-3-Pivotal-Studies-of-Emgality-R-galcanezumab-gnlm-Show-Improvements-in-Daily-Functioning-and-Reductions-in-Disability-in-Patients-with-Chronic-and-Episodic-Migraine,2019-07-12T00:00:00,clinical trial update
Lilly Announces Changes in Senior Leadership,https://lilly.mediaroom.com/2019-07-11-Lilly-Announces-Changes-in-Senior-Leadership,2019-07-11T00:00:00,management update
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache,https://lilly.mediaroom.com/2019-07-11-New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-Data-for-Emgality-R-galcanezumab-gnlm-in-Episodic-Cluster-Headache,2019-07-11T00:00:00,clinical trial update
Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment,https://lilly.mediaroom.com/2019-07-10-Lilly-Announces-Upcoming-Presentation-of-New-Data-Indicating-Rise-in-Opioid-Use-for-Migraine-Treatment,2019-07-10T00:00:00,clinical trial update
Lilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement,https://lilly.mediaroom.com/2019-07-09-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2019-Financial-Results-Announcement,2019-07-09T00:00:00,financial news
Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes,https://lilly.mediaroom.com/2019-06-26-Lillys-AWARD-11-trial-studying-higher-investigational-doses-of-Trulicity-R-dulaglutide-demonstrated-superiority-in-A1C-reduction-in-people-with-type-2-diabetes,2019-06-26T00:00:00,clinical trial update
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure,https://lilly.mediaroom.com/2019-06-26-U-S-FDA-Grants-Fast-Track-Designation-to-Empagliflozin-for-the-Treatment-of-Chronic-Heart-Failure,2019-06-26T00:00:00,regulatory approval
Lilly Declares Third-Quarter 2019 Dividend,https://lilly.mediaroom.com/2019-06-19-Lilly-Declares-Third-Quarter-2019-Dividend,2019-06-19T00:00:00,financial news
Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology,https://lilly.mediaroom.com/2019-06-14-Lilly-Presents-Positive-Results-for-Taltz-R-ixekizumab-vs-Humira-R-adalimumab-in-a-Head-to-Head-SPIRIT-H2H-Superiority-Study-in-Patients-with-Active-Psoriatic-Arthritis-at-the-European-Congress-of-Rheumatology,2019-06-14T00:00:00,clinical trial update
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology,https://lilly.mediaroom.com/2019-06-11-Lilly-to-Present-5-Year-Sustained-Efficacy-and-Safety-Results-for-Taltz-R-ixekizumab-in-Patients-with-Plaque-Psoriasis-at-the-World-Congress-of-Dermatology,2019-06-11T00:00:00,clinical trial update
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®,https://lilly.mediaroom.com/2019-06-10-Detailed-findings-from-CAROLINA-R-outcome-trial-support-long-term-cardiovascular-safety-profile-of-Tradjenta-R,2019-06-10T00:00:00,clinical trial update
"New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria",https://lilly.mediaroom.com/2019-06-10-New-analysis-shows-cardiorenal-risk-reductions-of-Jardiance-R-are-consistent-in-adults-with-type-2-diabetes-cardiovascular-disease-and-kidney-disease-without-overt-proteinuria,2019-06-10T00:00:00,clinical trial update
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes,https://lilly.mediaroom.com/2019-06-09-Trulicity-R-dulaglutide-significantly-reduced-major-cardiovascular-events-for-broad-range-of-people-with-type-2-diabetes,2019-06-09T00:00:00,clinical trial update
"Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions",https://lilly.mediaroom.com/2019-06-09-Lillys-ultra-rapid-lispro-provided-similar-A1C-reductions-compared-to-Humalog-R-insulin-lispro-with-superior-post-meal-blood-glucose-reductions,2019-06-09T00:00:00,clinical trial update
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions®,https://lilly.mediaroom.com/2019-06-08-Lillys-tirzepatide-demonstrates-benefits-in-data-presented-at-the-American-Diabetes-Associations-R-79-Scientific-Sessions-R,2019-06-08T00:00:00,clinical trial update
Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology,https://lilly.mediaroom.com/2019-06-06-Lilly-to-Present-New-Data-and-Commitment-to-Patient-Centered-Solutions-at-the-Annual-European-Congress-of-Rheumatology,2019-06-06T00:00:00,clinical trial update
Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology,https://lilly.mediaroom.com/2019-06-05-Lilly-to-Showcase-Scientific-Innovation-within-Dermatology-Portfolio-at-24th-World-Congress-of-Dermatology,2019-06-05T00:00:00,clinical trial update
FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks,https://lilly.mediaroom.com/2019-06-04-FDA-Approves-Emgality-R-galcanezumab-gnlm-as-the-First-and-Only-Medication-for-the-Treatment-of-Episodic-Cluster-Headache-that-Reduces-the-Frequency-of-Attacks,2019-06-04T00:00:00,regulatory approval
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes,https://lilly.mediaroom.com/2019-06-04-U-S-FDA-Accepts-New-Drug-Application-for-Triple-Combination-Tablet-for-Adults-with-Type-2-Diabetes,2019-06-04T00:00:00,regulatory approval
Hurricane Season is Almost Here. Are You Ready?,https://lilly.mediaroom.com/2019-05-31-Hurricane-Season-is-Almost-Here-Are-You-Ready,2019-05-31T00:00:00,corporate
Lilly to Participate in Goldman Sachs Global Healthcare Conference,https://lilly.mediaroom.com/2019-05-30-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference,2019-05-30T00:00:00,corporate
Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio,https://lilly.mediaroom.com/2019-05-29-Lilly-Announces-Webcast-to-Discuss-ADA-Presentations-and-Diabetes-Portfolio,2019-05-29T00:00:00,clinical trial update
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics,https://lilly.mediaroom.com/2019-05-28-Lilly-Announces-Licensing-Agreement-for-Non-Opioid-Pain-Asset-from-Centrexion-Therapeutics,2019-05-28T00:00:00,commercialized drug update
Lilly's Lower-Priced Insulin Now Available,https://lilly.mediaroom.com/2019-05-22-Lillys-Lower-Priced-Insulin-Now-Available,2019-05-22T00:00:00,commercialized drug update
"Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions",https://lilly.mediaroom.com/2019-05-21-Lillys-Mirikizumab-Met-Primary-Endpoint-and-Key-Secondary-Endpoints-in-Phase-2-Study-Including-Reductions-of-Gastrointestinal-Lesions,2019-05-21T00:00:00,clinical trial update
Lilly to Participate in UBS Global Healthcare Conference,https://lilly.mediaroom.com/2019-05-16-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference,2019-05-16T00:00:00,corporate
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer,https://lilly.mediaroom.com/2019-05-15-Data-Presentations-at-ASCO-2019-Highlight-Lillys-Targeted-Approach-to-Developing-Treatments-for-Patients-Living-with-Cancer,2019-05-15T00:00:00,clinical trial update
Lilly to Participate in Bank of America Merrill Lynch Health Care Conference,https://lilly.mediaroom.com/2019-05-15-Lilly-to-Participate-in-Bank-of-America-Merrill-Lynch-Health-Care-Conference,2019-05-15T00:00:00,corporate
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma,https://lilly.mediaroom.com/2019-05-13-Lillys-CYRAMZA-R-ramucirumab-Becomes-First-FDA-Approved-Biomarker-Driven-Therapy-in-Patients-with-Hepatocellular-Carcinoma,2019-05-13T00:00:00,regulatory approval
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience,https://lilly.mediaroom.com/2019-05-08-AAN-2019-Two-New-Analyses-of-Lasmiditan-Phase-3-Studies-Measured-Onset-of-Effect-and-the-Effect-of-Lasmiditan-in-Patients-with-Prior-Triptan-Experience,2019-05-08T00:00:00,clinical trial update
Lilly Declares Second-Quarter 2019 Dividend,https://lilly.mediaroom.com/2019-05-06-Lilly-Declares-Second-Quarter-2019-Dividend,2019-05-06T00:00:00,financial news
AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups,https://lilly.mediaroom.com/2019-05-06-AAN-2019-Pooled-Analyses-of-Two-Emgality-R-galcanezumab-gnlm-Phase-3-Studies-Show-Reduction-in-Monthly-Migraine-Headache-Days-in-Low-and-High-Frequency-Episodic-Migraine-Subgroups,2019-05-06T00:00:00,clinical trial update
Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio,https://lilly.mediaroom.com/2019-05-02-Lilly-to-Present-New-Data-at-AAN-2019-on-Emgality-R-galcanezumab-gnlm-and-Lasmiditan-Reinforcing-Breadth-of-Headache-Disorders-Portfolio,2019-05-02T00:00:00,clinical trial update
"Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health",https://lilly.mediaroom.com/2019-04-30-Lilly-Reports-Solid-First-Quarter-2019-Financial-Results-Updates-2019-Guidance-to-Reflect-Disposition-of-Elanco-Animal-Health,2019-04-30T00:00:00,financial news
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit,https://lilly.mediaroom.com/2019-04-26-U-S-Court-of-Appeals-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit,2019-04-26T00:00:00,regulatory approval
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market,https://lilly.mediaroom.com/2019-04-25-Lilly-to-Establish-an-Access-Program-for-Patients-as-it-Prepares-to-Withdraw-Lartruvo-from-the-Global-Market,2019-04-25T00:00:00,commercialized drug update
Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China,https://lilly.mediaroom.com/2019-04-22-Lilly-Announces-Sale-of-Legacy-Antibiotics-Brands-and-Manufacturing-Facility-in-China,2019-04-22T00:00:00,commercialized drug update
"Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",https://lilly.mediaroom.com/2019-04-22-Lilly-Announces-Positive-Top-Line-Results-for-COAST-X-a-52-Week-Placebo-Controlled-Study-of-Taltz-R-ixekizumab-in-Patients-with-Non-Radiographic-Axial-Spondyloarthritis,2019-04-22T00:00:00,clinical trial update
Lilly and Avidity Biosciences Announce Licensing and Research Collaboration,https://lilly.mediaroom.com/2019-04-22-Lilly-and-Avidity-Biosciences-Announce-Licensing-and-Research-Collaboration,2019-04-22,Licensing and Research Collaboration
Pfizer and Lilly Announce Top-Line Results from Long-Term Phase 3 Study of Tanezumab in Patients with Osteoarthritis,https://lilly.mediaroom.com/2019-04-18-Pfizer-and-Lilly-Announce-Top-Line-Results-from-Long-Term-Phase-3-Study-of-Tanezumab-in-Patients-with-Osteoarthritis,2019-04-18,Clinical trial update
Lilly and ImmuNext Announce Licensing and Research Collaboration,https://lilly.mediaroom.com/2019-03-26-Lilly-and-ImmuNext-Announce-Licensing-and-Research-Collaboration,2019-03-26,Licensing and Research Collaboration
Survey Reveals Genital Psoriasis May Reduce Patients’ Self-Confidence and Hinder Them from Having Close Relationships,https://lilly.mediaroom.com/2019-03-21-Survey-Reveals-Genital-Psoriasis-May-Reduce-Patients-Self-Confidence-and-Hinder-Them-from-Having-Close-Relationships,2019-03-21,Commercialized drug update
NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology,https://lilly.mediaroom.com/2019-03-20-NCCN-Announces-Six-Quality-Improvement-Projects-in-Gastric-Cancer-Care-Approved-for-Collaboration-with-Lilly-Oncology,2019-03-20,Collaboration
Lilly Announces Final Results of Elanco Exchange Offer,https://lilly.mediaroom.com/2019-03-13-Lilly-Announces-Final-Results-of-Elanco-Exchange-Offer,2019-03-13,Financial news
"Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",https://lilly.mediaroom.com/2019-03-12-Lillys-CYRAMZA-R-ramucirumab-Phase-3-RELAY-Trial-Met-Primary-Endpoint-Significantly-Improving-Progression-Free-Survival-in-First-Line-Treatment-of-Patients-with-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer,2019-03-12,Clinical trial update
Lilly Announces Preliminary Results of Elanco Exchange Offer,https://lilly.mediaroom.com/2019-03-11-Lilly-Announces-Preliminary-Results-of-Elanco-Exchange-Offer,2019-03-11,Financial news
Lilly to Participate in Barclays Global Healthcare Conference,https://lilly.mediaroom.com/2019-03-08-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference,2019-03-08,Management update
Lilly to Participate in Cowen Health Care Conference,https://lilly.mediaroom.com/2019-03-07-Lilly-to-Participate-in-Cowen-Health-Care-Conference,2019-03-07,Management update
Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer,https://lilly.mediaroom.com/2019-03-07-Lilly-Announces-Final-Exchange-Ratio-of-4-5121-for-Elanco-Exchange-Offer,2019-03-07,Financial news
Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults,https://lilly.mediaroom.com/2019-03-05-Lilly-Receives-FDA-Priority-Review-Designation-for-Emgality-R-galcanezumab-gnlm-Injection-for-the-Preventive-Treatment-of-Episodic-Cluster-Headache-in-Adults,2019-03-05,Regulatory approval
Lilly to Introduce Lower-Priced Insulin,https://lilly.mediaroom.com/2019-03-04-Lilly-to-Introduce-Lower-Priced-Insulin,2019-03-04,Commercialized drug update
Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting,https://lilly.mediaroom.com/2019-03-01-Lilly-to-Present-Data-Demonstrating-Continued-Scientific-Advancements-in-Broad-Dermatology-Portfolio-at-AAD-Annual-Meeting,2019-03-01,Commercialized drug update
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain,https://lilly.mediaroom.com/2019-02-19-Pfizer-and-Lilly-Announce-Top-line-Results-From-Phase-3-Study-of-Tanezumab-in-Chronic-Low-Back-Pain,2019-02-19,Clinical trial update
Lilly Completes Acquisition of Loxo Oncology,https://lilly.mediaroom.com/2019-02-15-Lilly-Completes-Acquisition-of-Loxo-Oncology,2019-02-15,Financial news
Lilly To Participate in Leerink Partners Global Healthcare Conference,https://lilly.mediaroom.com/2019-02-14-Lilly-To-Participate-in-Leerink-Partners-Global-Healthcare-Conference,2019-02-14,Management update
Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride,https://lilly.mediaroom.com/2019-02-14-Boehringer-Ingelheim-and-Lilly-announce-the-CAROLINA-R-cardiovascular-outcome-trial-of-Tradjenta-R-met-its-primary-endpoint-of-non-inferiority-compared-with-glimepiride,2019-02-14,Clinical trial update
Lilly to Participate in Guggenheim Healthcare Talks Idea Forum,https://lilly.mediaroom.com/2019-02-08-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-Idea-Forum,2019-02-08,Management update
Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health,https://lilly.mediaroom.com/2019-02-08-Lilly-Will-Initiate-Divestiture-of-its-Remaining-Interest-in-Elanco-Animal-Health,2019-02-08,Financial news
"Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology",https://lilly.mediaroom.com/2019-02-06-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2018-Financial-Results-Lowers-2019-EPS-Guidance-to-Reflect-the-Pending-Acquisition-of-Loxo-Oncology,2019-02-06,Financial news
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis,https://lilly.mediaroom.com/2019-02-04-Lilly-Announces-Top-Line-Phase-3-Results-for-Baricitinib-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis,2019-02-04,Clinical trial update
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction,https://lilly.mediaroom.com/2019-02-01-Lilly-and-Loxo-Oncology-Announce-Expiration-of-HSR-Act-Waiting-Period-in-Connection-with-Proposed-Transaction,2019-02-01,Financial news
FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer,https://lilly.mediaroom.com/2019-01-31-FDA-Expands-Lillys-ALIMTA-R-pemetrexed-Label-with-Combination-of-KEYTRUDA-R-pembrolizumab-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-Metastatic-Nonsquamous-Non-Small-Cell-Lung-Cancer,2019-01-31,Regulatory approval
Lilly Revises Date for Fourth-Quarter 2018 Financial Results Announcement,https://lilly.mediaroom.com/2019-01-30-Lilly-Revises-Date-for-Fourth-Quarter-2018-Financial-Results-Announcement,2019-01-30,Financial news
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain,https://lilly.mediaroom.com/2019-01-29-Pfizer-and-Lilly-Announce-Top-Line-Results-From-Second-Phase-3-Study-of-Tanezumab-in-Osteoarthritis-Pain,2019-01-29,Clinical trial update
Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin,https://lilly.mediaroom.com/2019-01-23-Government-Employees-Affected-by-Federal-Shutdown-Encouraged-to-Contact-Lilly-Diabetes-Solution-Center-to-Access-Insulin,2019-01-23,Commercialized drug update
Lilly Confirms Date and Conference Call for Fourth-Quarter 2018 Financial Results Announcement,https://lilly.mediaroom.com/2019-01-21-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2018-Financial-Results-Announcement,2019-01-21,Financial news
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients,https://lilly.mediaroom.com/2019-01-18-Lilly-Phase-3-REACH-2-Trial-Data-Published-in-The-Lancet-Oncology-Shows-Improvement-in-Overall-Survival-with-CYRAMZA-R-ramucirumab-in-Second-Line-AFP-High-Hepatocellular-Carcinoma-Patients,2019-01-18,Clinical trial update
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®,https://lilly.mediaroom.com/2019-01-18-Lilly-Reports-Results-of-Phase-3-Soft-Tissue-Sarcoma-Study-of-LARTRUVO-R,2019-01-18,Clinical trial update
Lilly Announces Agreement To Acquire Loxo Oncology,https://lilly.mediaroom.com/2019-01-07-Lilly-Announces-Agreement-To-Acquire-Loxo-Oncology,2019-01-07,Financial news
Lilly to Participate in J.P. Morgan Healthcare Conference,https://lilly.mediaroom.com/2019-01-03-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference,2019-01-03,Management update
"Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting",https://lilly.mediaroom.com/2018-12-19-Lilly-Announces-Financial-Guidance-Reviews-Commercial-Performance-and-Highlights-Promising-Pipeline-Opportunities-at-Investment-Community-Meeting,2018-12-19,Financial news
Lilly Announces 15 Percent Dividend Increase,https://lilly.mediaroom.com/2018-12-19-Lilly-Announces-15-Percent-Dividend-Increase,2018-12-19,Financial news
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies,https://lilly.mediaroom.com/2018-12-18-Lilly-and-Aduro-Biotech-Announce-Research-Collaboration-and-License-Agreement-to-Develop-Novel-Immunotherapies,2018-12-18,Licensing and Research Collaboration
Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis,https://lilly.mediaroom.com/2018-12-18-Lilly-announces-publication-of-analyses-showing-benefit-of-the-addition-of-Verzenio-R-abemaciclib-in-multiple-subgroups-of-patients-with-advanced-breast-cancer-identified-as-having-a-more-concerning-prognosis,2018-12-18,Clinical trial update
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis,https://lilly.mediaroom.com/2018-12-17-Lilly-Announces-Positive-Top-Line-Results-for-Taltz-R-ixekizumab-vs-Humira-R-adalimumab-in-a-Head-to-Head-SPIRIT-H2H-Superiority-Study-in-Patients-with-Active-Psoriatic-Arthritis,2018-12-17,Clinical trial update
Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences,https://lilly.mediaroom.com/2018-12-14-Lilly-to-Acquire-Pre-Clinical-Pain-Program-from-Hydra-Biosciences,2018-12-14,Licensing and Research Collaboration
Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors,https://lilly.mediaroom.com/2018-12-14-Lilly-and-Evidation-Health-Expand-Collaboration-to-Analyze-Data-from-Smartphones-and-Connected-Sensors,2018-12-14,Collaboration
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE),https://lilly.mediaroom.com/2018-12-13-FDA-Grants-Fast-Track-Designation-to-the-Baricitinib-Development-Program-for-the-Treatment-of-Systemic-Lupus-Erythematosus-SLE,2018-12-13,Regulatory approval
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease,https://lilly.mediaroom.com/2018-12-13-Boehringer-Ingelheim-and-Lilly-Partner-with-Duke-Clinical-Research-Institute-to-Advance-Multidisciplinary-Care-for-People-with-Type-2-Diabetes-and-Cardiovascular-Disease,2018-12-13,Collaboration
Lilly and AC Immune Announce License and Collaboration Agreement,https://lilly.mediaroom.com/2018-12-12-Lilly-and-AC-Immune-Announce-License-and-Collaboration-Agreement,2018-12-12,Licensing and Research Collaboration
NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment,https://lilly.mediaroom.com/2018-12-03-NCCN-Oncology-Research-Program-Awarded-2-Million-from-Lilly-to-Study-Mechanisms-of-Resistance-to-CDK4-6-Inhibitors-in-Breast-Cancer-Treatment,2018-12-03,Collaboration
"Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS",https://lilly.mediaroom.com/2018-11-29-Lilly-to-Present-Clinical-Data-for-Verzenio-R-abemaciclib-and-Real-World-Evidence-across-HR-HER2-Metastatic-Breast-Cancer-at-2018-SABCS,2018-11-29,Clinical trial update
"Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting",https://lilly.mediaroom.com/2018-11-27-Lilly-to-Announce-2019-Financial-Guidance-Highlight-Late-Stage-Pipeline-Opportunities-and-Discuss-Commercial-Performance-at-Upcoming-Investment-Community-Meeting,2018-11-27,Financial news
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway,https://lilly.mediaroom.com/2018-11-26-Jardiance-R-Recommended-as-Preferred-SGLT2-Inhibitor-for-Adults-with-Type-2-Diabetes-and-Established-Cardiovascular-Disease-in-American-College-of-Cardiology-Expert-Consensus-Decision-Pathway,2018-11-26,Commercialized drug update
"Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache",https://lilly.mediaroom.com/2018-11-14-Lilly-Submits-New-Drug-Application-to-the-FDA-for-Lasmiditan-for-Acute-Treatment-of-Migraine-Receives-Breakthrough-Therapy-Designation-for-Emgality-TM-galcanezumab-gnlm-for-Prevention-of-Episodic-Cluster-Headache,2018-11-14,Regulatory approval
Lilly to Participate in Credit Suisse 27th Annual Healthcare Conference,https://lilly.mediaroom.com/2018-11-08-Lilly-to-Participate-in-Credit-Suisse-27th-Annual-Healthcare-Conference,2018-11-08,Management update
"Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance",https://lilly.mediaroom.com/2018-11-06-Lilly-Delivers-Solid-Third-Quarter-2018-Results-Revises-EPS-Guidance,2018-11-06,Financial news
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines,https://lilly.mediaroom.com/2018-11-05-Lilly-and-NextCure-Announce-Collaboration-to-Discover-and-Develop-Novel-Immuno-Oncology-Medicines,2018-11-05,Licensing and Research Collaboration
